CA3230155A1 - Growth hormone antagonist and anti-cancer composition combination therapy - Google Patents
Growth hormone antagonist and anti-cancer composition combination therapy Download PDFInfo
- Publication number
- CA3230155A1 CA3230155A1 CA3230155A CA3230155A CA3230155A1 CA 3230155 A1 CA3230155 A1 CA 3230155A1 CA 3230155 A CA3230155 A CA 3230155A CA 3230155 A CA3230155 A CA 3230155A CA 3230155 A1 CA3230155 A1 CA 3230155A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- composition
- growth hormone
- human growth
- hormone receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 25
- 229940122853 Growth hormone antagonist Drugs 0.000 title claims abstract description 9
- 238000002648 combination therapy Methods 0.000 title description 9
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 88
- 229940124013 Growth hormone receptor antagonist Drugs 0.000 claims abstract description 62
- 108010005905 delta-hGHR Proteins 0.000 claims abstract description 61
- 201000011510 cancer Diseases 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 20
- 108010000521 Human Growth Hormone Proteins 0.000 claims abstract description 9
- 102000002265 Human Growth Hormone Human genes 0.000 claims abstract description 9
- 239000000854 Human Growth Hormone Substances 0.000 claims abstract description 9
- 238000001574 biopsy Methods 0.000 claims abstract description 9
- 230000004043 responsiveness Effects 0.000 claims abstract description 4
- 238000012216 screening Methods 0.000 claims abstract description 3
- 102100020948 Growth hormone receptor Human genes 0.000 claims description 71
- 108010068542 Somatotropin Receptors Proteins 0.000 claims description 69
- 229920001223 polyethylene glycol Polymers 0.000 claims description 46
- 108010002519 Prolactin Receptors Proteins 0.000 claims description 44
- 102100029000 Prolactin receptor Human genes 0.000 claims description 44
- 150000001875 compounds Chemical class 0.000 claims description 41
- 239000002202 Polyethylene glycol Substances 0.000 claims description 37
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 37
- 229960005277 gemcitabine Drugs 0.000 claims description 37
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 36
- 238000011282 treatment Methods 0.000 claims description 31
- 230000007705 epithelial mesenchymal transition Effects 0.000 claims description 30
- 235000018417 cysteine Nutrition 0.000 claims description 28
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 27
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 26
- 201000002528 pancreatic cancer Diseases 0.000 claims description 26
- 235000001014 amino acid Nutrition 0.000 claims description 22
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 22
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 22
- 206010006187 Breast cancer Diseases 0.000 claims description 18
- 208000026310 Breast neoplasm Diseases 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 229960004679 doxorubicin Drugs 0.000 claims description 18
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 claims description 16
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 206010009944 Colon cancer Diseases 0.000 claims description 14
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 12
- 229930013930 alkaloid Natural products 0.000 claims description 12
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 12
- 229940100198 alkylating agent Drugs 0.000 claims description 12
- 239000002168 alkylating agent Substances 0.000 claims description 12
- 230000000340 anti-metabolite Effects 0.000 claims description 12
- 229940100197 antimetabolite Drugs 0.000 claims description 12
- 239000002256 antimetabolite Substances 0.000 claims description 12
- 239000003972 antineoplastic antibiotic Substances 0.000 claims description 12
- 201000001441 melanoma Diseases 0.000 claims description 12
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 12
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 9
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 9
- 238000002626 targeted therapy Methods 0.000 claims description 9
- 206010000599 Acromegaly Diseases 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- -1 carboxylate anions Chemical class 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 206010014733 Endometrial cancer Diseases 0.000 claims description 7
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 7
- 206010029260 Neuroblastoma Diseases 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- 230000021615 conjugation Effects 0.000 claims description 7
- 108010012154 cytokine inducible SH2-containing protein Proteins 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 206010027191 meningioma Diseases 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 6
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 6
- 101710132484 Cytokine-inducible SH2-containing protein Proteins 0.000 claims description 6
- 108010092160 Dactinomycin Proteins 0.000 claims description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 6
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 6
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 229930012538 Paclitaxel Natural products 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 6
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 6
- 229960002092 busulfan Drugs 0.000 claims description 6
- 201000007455 central nervous system cancer Diseases 0.000 claims description 6
- 229960004630 chlorambucil Drugs 0.000 claims description 6
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical group OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 6
- 229960004316 cisplatin Drugs 0.000 claims description 6
- 229960004397 cyclophosphamide Drugs 0.000 claims description 6
- 229960000684 cytarabine Drugs 0.000 claims description 6
- 229960000640 dactinomycin Drugs 0.000 claims description 6
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 6
- 229960005420 etoposide Drugs 0.000 claims description 6
- 229960002949 fluorouracil Drugs 0.000 claims description 6
- 229960000908 idarubicin Drugs 0.000 claims description 6
- 229960004768 irinotecan Drugs 0.000 claims description 6
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims description 6
- 229960001428 mercaptopurine Drugs 0.000 claims description 6
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 6
- 229960001156 mitoxantrone Drugs 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 229960001592 paclitaxel Drugs 0.000 claims description 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 6
- 229960001196 thiotepa Drugs 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- 229960003862 vemurafenib Drugs 0.000 claims description 6
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 6
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 6
- 229960004528 vincristine Drugs 0.000 claims description 6
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 6
- 102220587327 NEDD8-activating enzyme E1 catalytic subunit_H21N_mutation Human genes 0.000 claims description 4
- 150000001945 cysteines Chemical class 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims 2
- 230000014509 gene expression Effects 0.000 description 63
- 102000018997 Growth Hormone Human genes 0.000 description 51
- 108010051696 Growth Hormone Proteins 0.000 description 51
- 239000000122 growth hormone Substances 0.000 description 50
- 239000005557 antagonist Substances 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 41
- 239000003814 drug Substances 0.000 description 36
- 229940079593 drug Drugs 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 27
- 108700037519 pegvisomant Proteins 0.000 description 24
- 229960002995 pegvisomant Drugs 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 102000005962 receptors Human genes 0.000 description 19
- 108020003175 receptors Proteins 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 14
- 239000000556 agonist Substances 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000011580 nude mouse model Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 6
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 6
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 6
- 229940041181 antineoplastic drug Drugs 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 238000009650 gentamicin protection assay Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000009097 single-agent therapy Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 239000003560 cancer drug Substances 0.000 description 4
- 239000012830 cancer therapeutic Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000006320 pegylation Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 101710099093 Growth hormone receptor Proteins 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001944 cysteine derivatives Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102100028161 ATP-binding cassette sub-family C member 2 Human genes 0.000 description 2
- 102100022594 ATP-binding cassette sub-family G member 1 Human genes 0.000 description 2
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 2
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 2
- 102100036364 Cadherin-2 Human genes 0.000 description 2
- 102000038594 Cdh1/Fizzy-related Human genes 0.000 description 2
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- 101000714537 Homo sapiens Cadherin-2 Proteins 0.000 description 2
- 101000803403 Homo sapiens Vimentin Proteins 0.000 description 2
- 101000785626 Homo sapiens Zinc finger E-box-binding homeobox 1 Proteins 0.000 description 2
- 101000633054 Homo sapiens Zinc finger protein SNAI2 Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
- 108010090314 Member 1 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 2
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 2
- 102100028134 Mitochondrial potassium channel ATP-binding subunit Human genes 0.000 description 2
- 101710106113 Mitochondrial potassium channel ATP-binding subunit Proteins 0.000 description 2
- 108010066419 Multidrug Resistance-Associated Protein 2 Proteins 0.000 description 2
- 102100024819 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 description 2
- 102100035071 Vimentin Human genes 0.000 description 2
- 102100026457 Zinc finger E-box-binding homeobox 1 Human genes 0.000 description 2
- 102100029570 Zinc finger protein SNAI2 Human genes 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 210000004198 anterior pituitary gland Anatomy 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 2
- 210000004349 growth plate Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940125425 inverse agonist Drugs 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- VKLOPQHLJNFYKK-UHFFFAOYSA-N 3-dodecylsulfanylpropanoic acid Chemical compound CCCCCCCCCCCCSCCC(O)=O VKLOPQHLJNFYKK-UHFFFAOYSA-N 0.000 description 1
- 102100021501 ATP-binding cassette sub-family B member 5 Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100040836 Claudin-1 Human genes 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102100036448 Endothelial PAS domain-containing protein 1 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100023590 Fibroblast growth factor-binding protein 1 Human genes 0.000 description 1
- 206010018265 Gigantism Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000677872 Homo sapiens ATP-binding cassette sub-family B member 5 Proteins 0.000 description 1
- 101000749331 Homo sapiens Claudin-1 Proteins 0.000 description 1
- 101000827725 Homo sapiens Fibroblast growth factor-binding protein 1 Proteins 0.000 description 1
- 101000969812 Homo sapiens Multidrug resistance-associated protein 1 Proteins 0.000 description 1
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
- 101000635958 Homo sapiens Transforming growth factor beta-2 proprotein Proteins 0.000 description 1
- 101000723833 Homo sapiens Zinc finger E-box-binding homeobox 2 Proteins 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 108091006006 PEGylated Proteins Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000058018 Suppressor of Cytokine Signaling 1 Human genes 0.000 description 1
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 description 1
- 102100024779 Suppressor of cytokine signaling 1 Human genes 0.000 description 1
- 102100024784 Suppressor of cytokine signaling 2 Human genes 0.000 description 1
- 101710137422 Suppressor of cytokine signaling 2 Proteins 0.000 description 1
- 102100024283 Suppressor of cytokine signaling 3 Human genes 0.000 description 1
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- 102100030737 Transforming growth factor beta-2 proprotein Human genes 0.000 description 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010083162 Twist-Related Protein 1 Proteins 0.000 description 1
- 108010083176 Twist-Related Protein 2 Proteins 0.000 description 1
- 102100030398 Twist-related protein 1 Human genes 0.000 description 1
- 102100031720 Twist-related protein 2 Human genes 0.000 description 1
- 102100028458 Zinc finger E-box-binding homeobox 2 Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229940075620 somatostatin analogue Drugs 0.000 description 1
- 210000001764 somatotrope Anatomy 0.000 description 1
- 210000001875 somatotroph Anatomy 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 229940099077 somavert Drugs 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A composition for treating a disease or condition responsive to human growth hormone receptor antagonists, comprising a modified human growth hormone receptor antagonist; and an anti-cancer composition. A method for treating cancer using human growth hormone antagonists, comprising pre-screening a patient by analyzing a tumor biopsy to confirm the presence of cancer and the presence of certain predetermined factors indicative of responsiveness to human growth hormone antagonists; and treating the patient with an effective amount of a composition that includes a modified human growth hormone receptor antagonist and an anti-cancer composition.
Description
TITLE
GROWTH HORMONE ANTAGONIST AND ANTI-CANCER COMPOSITION
COMBINATION THERAPY
REFERENCE TO A SEQUENCE LISTING
[0001] A sequence listing in computer readable form (CRF) is on file. The sequence listing is in an ASCII text (.txt) file entitled SEQIDNOS 1 4 ST25 CIPl.txt created on August 20, 2021, and is 6 KB in size. The sequence listing is incorporated by reference as if fully recited herein.
BACKGROUND
GROWTH HORMONE ANTAGONIST AND ANTI-CANCER COMPOSITION
COMBINATION THERAPY
REFERENCE TO A SEQUENCE LISTING
[0001] A sequence listing in computer readable form (CRF) is on file. The sequence listing is in an ASCII text (.txt) file entitled SEQIDNOS 1 4 ST25 CIPl.txt created on August 20, 2021, and is 6 KB in size. The sequence listing is incorporated by reference as if fully recited herein.
BACKGROUND
[0002] The disclosed inventive technology relates in general to compositions and methods for treating cancer and other diseases, and more specifically to a combination therapy for treating cancer that includes a growth hormone antagonist combined with at least one anti-cancer composition, substance, or drug, wherein the combination therapy prevents the development of drug resistance.
[0003] Human growth hormone (hGH or GH), also known as somatotropin or somatropin, is a peptide hormone that stimulates growth, cell reproduction, and regeneration in humans and other animals. Growth hormone is a type of mitogen that is specific only to certain kinds of cells and is a 191-amino acid, single-chain polypeptide that is synthesized, stored, and secreted by somatotropic cells within the lateral wings of the anterior pituitary gland.
Acromegaly is a syndrome that results when the anterior pituitary gland produces excess GH
after epiphyseal plate closure at puberty. If GH is produced in excess prior to epiphyseal plate closure, the result is gigantism (or giantism). A number of disorders may increase pituitary GH
output, although most commonly it involves a tumor called pituitary adenoma, derived from a distinct type of cell (somatotrophs). Acromegaly most commonly affects adults in middle age and can result in severe disfigurement, complicating conditions, and premature death if untreated.
Because of its pathogenesis and slow progression, the disease is hard to diagnose in the early stages and is frequently missed for years until changes in external features, especially of the face, become noticeable.
Acromegaly is a syndrome that results when the anterior pituitary gland produces excess GH
after epiphyseal plate closure at puberty. If GH is produced in excess prior to epiphyseal plate closure, the result is gigantism (or giantism). A number of disorders may increase pituitary GH
output, although most commonly it involves a tumor called pituitary adenoma, derived from a distinct type of cell (somatotrophs). Acromegaly most commonly affects adults in middle age and can result in severe disfigurement, complicating conditions, and premature death if untreated.
Because of its pathogenesis and slow progression, the disease is hard to diagnose in the early stages and is frequently missed for years until changes in external features, especially of the face, become noticeable.
[0004] A receptor is a protein molecule usually found embedded within the plasma membrane surface of a cell that receives chemical signals from outside the cell. When such chemical signals bind to a receptor these signals cause some form of cellular/tissue response such as, for example, a change in the electrical activity of the cell. In this sense, a receptor is a protein molecule that recognizes and responds to endogenous chemical signals. An agonist, such as human growth hormone, is a chemical composition that binds to a receptor and activates the receptor to produce a biological response. Whereas an agonist causes an action, an antagonist blocks the action of the agonist, and an inverse agonist causes an action opposite to that of the agonist. A receptor antagonist is a type of receptor ligand or drug that blocks or dampens agonist-mediated responses rather than provoking a biological response itself upon binding to a receptor.
These compositions are sometimes called blockers and examples include alpha blockers, beta blockers, and calcium channel blockers.
These compositions are sometimes called blockers and examples include alpha blockers, beta blockers, and calcium channel blockers.
[0005] In pharmacology, antagonists have affinity but no efficacy for their cognate receptors, and binding will disrupt the interaction and inhibit the function of an agonist or inverse agonist at receptors. Antagonists mediate their effects by binding to the active (orthosteric) site or to other (allosteric) sites on receptors, or they may interact at unique binding sites not normally involved in the biological regulation of the receptor's activity. Antagonist activity may be reversible or irreversible depending on the longevity of the antagonist¨receptor complex, which, in turn, depends on the nature of antagonist¨receptor binding. Most drug antagonists achieve their potency by competing with endogenous ligands or substrates at structurally defined binding sites on receptors. By definition, antagonists display no efficacy to activate the receptors they bind, and antagonists do not maintain the ability to activate a receptor. Once bound, however, antagonists inhibit the function of agonists, inverse agonists, and partial agonists.
[0006] Growth hormone receptor antagonists such as the product pegvisomant (sold under the trademark SOMAVERT ) are used in the treatment of acromegaly. Such compositions are used if the tumor of the pituitary gland causing the acromegaly cannot be controlled with surgery or radiation and the use of somatostatin analogues is unsuccessful.
Pegvisomant is typically delivered as a powder that is mixed with water and injected under the skin.
Pegvisomant is typically delivered as a powder that is mixed with water and injected under the skin.
[0007] Pegylation is the process of both covalent and non-covalent amalgamation of polyethylene glycol (PEG) polymer chains to molecules and macrostructures, such as drugs, peptides, antibody fragments, or therapeutic proteins. Pegylation is routinely achieved by incubation of a reactive derivative of PEG with the target molecule and produces alterations in physiochemical properties, including changes in molecular size and molecular charge. These physical and chemical changes increase systemic retention of the therapeutic agent and can influence the binding affinity of the therapeutic moiety to the cell receptors and can alter the absorption and distribution patterns. The covalent attachment of PEG to a drug or therapeutic protein can also "mask" the agent from the host's immune system (i.e., reducing immunogenicity and antigenicity), and increase the hydrodynamic size (i.e., size in solution) of the agent which prolongs its circulatory time by reducing renal clearance. Pegylation can also provide water solubility to hydrophobic drugs and proteins.
[0008] Pegylation, by increasing the molecular weight of a molecule, can impart several significant pharmacological advantages over the unmodified form of the molecule, such as: (i) improved drug solubility; (ii) reduced dosage frequency, without diminished efficacy and with potentially reduced toxicity; (iii) extended circulating life; (iv) increased drug stability; and (v) enhanced protection from proteolytic degradation. PEGylated drugs also include the following commercial advantages: (i) opportunities for new delivery formats and dosing regimens; and (ii) extended patent life of previously approved drugs. PEG is a particularly attractive polymer for conjugation and the specific characteristics of PEG moieties relevant to pharmaceutical applications include: (i) water solubility; (ii) high mobility in solution;
(iii) lack of toxicity and low immunogenicity; and (iv) altered distribution in the body.
(iii) lack of toxicity and low immunogenicity; and (iv) altered distribution in the body.
[0009] The addition of high molecular weight polyethylene glycols (PEGs) to proteins has been previously shown to increase the in-vivo half-lives of these proteins by a size dependent decrease in elimination by the kidneys. The addition of PEGs also lowers the immunogenicity of the proteins and decreases aggregation and protease cleavage [1]-[2]. Multiple known PEGylated proteins have been approved by the USFDA for therapeutic use, including hormones, cytokines, antibody fragments, and enzymes [1] and [3]-[4]. Thus, there is an ongoing need for the further development of PEGylated therapeutics, particularly for use in the treatment of diseases that are responsive to the use of GH receptor antagonists or other receptor antagonists.
[0010] Evidence from human studies [5], animal studies [6], and cancer cell line studies [6] supports a role for growth hormone (GH) in carcinogenesis. The relationship between GH
receptor (GHR) expression and function in the following human cancers has been reviewed; breast cancer, liver cancer, prostate cancer, colon cancer, melanoma, pancreatic cancer, endometrial cancer, meningioma, neuroblastoma, glioma, lung cancer, and stomach cancer [6]. Both in vitro studies with cancer cell lines and in vivo studies with human tumor xenografts in nude mice indicate that attenuating GH action has anti-cancer effects. The effects of GH
on cancer have been shown to be inhibited either by reducing the expression of the GH receptor (GHR) or by use of the GHR antagonist, pegvisomant [6]. There is also in vivo and in vitro evidence that, for breast and prostate cancers, attenuating prolactin (PRL) action has, in many cases, anti-cancer effects [7].
receptor (GHR) expression and function in the following human cancers has been reviewed; breast cancer, liver cancer, prostate cancer, colon cancer, melanoma, pancreatic cancer, endometrial cancer, meningioma, neuroblastoma, glioma, lung cancer, and stomach cancer [6]. Both in vitro studies with cancer cell lines and in vivo studies with human tumor xenografts in nude mice indicate that attenuating GH action has anti-cancer effects. The effects of GH
on cancer have been shown to be inhibited either by reducing the expression of the GH receptor (GHR) or by use of the GHR antagonist, pegvisomant [6]. There is also in vivo and in vitro evidence that, for breast and prostate cancers, attenuating prolactin (PRL) action has, in many cases, anti-cancer effects [7].
[0011] The use of GHR antagonists in cancer therapy is contingent on the cancer cells expressing the GHR or the prolactin receptor (PRLR) or both the GHR and PRLR.
The level of GHR expression and the level of PRLR expression has been determined in 60 cancer cell lines from nine types of human cancer: breast, CNS, colon, leukemia, melanoma, non-small cell lung, ovarian, prostate, and renal [8]. High GHR expression levels were obtained with most of the cell lines for all the cancer types except for colon cancer and leukemia. High PRLR
expression levels were obtained for most of the cell lines with all the cancer types except for leukemia and prostate cancer.
The level of GHR expression and the level of PRLR expression has been determined in 60 cancer cell lines from nine types of human cancer: breast, CNS, colon, leukemia, melanoma, non-small cell lung, ovarian, prostate, and renal [8]. High GHR expression levels were obtained with most of the cell lines for all the cancer types except for colon cancer and leukemia. High PRLR
expression levels were obtained for most of the cell lines with all the cancer types except for leukemia and prostate cancer.
[0012] Chemotherapy is the most common form of cancer treatment, but in many cases cancers develop resistance to chemotherapy over time [9]. This drug resistance is a major cause of cancer deaths. The effects of GH on the development of chemotherapy resistance have recently been reviewed [10]. Studies have used GH, GHR knockout mice (GHRKO), and the hGHR
antagonist, pegvisomant to investigate the effects of GH/GHR signaling on cancer drug resistance [10]. In vitro, studies with cancer cell lines indicate that GH promotes cancer drug resistance by protecting cells from apoptosis, stimulating the epithelial to mesenchymal transition (EMT), stimulating the expression of ATP-binding cassette (ABC) transporters (drug efflux pumps), and promotion of cancer stem cells. There is also evidence that PRE promotes cancer drug resistance by way of upregulating ABC transporters [11] and promoting cancer stem-like properties [12].
antagonist, pegvisomant to investigate the effects of GH/GHR signaling on cancer drug resistance [10]. In vitro, studies with cancer cell lines indicate that GH promotes cancer drug resistance by protecting cells from apoptosis, stimulating the epithelial to mesenchymal transition (EMT), stimulating the expression of ATP-binding cassette (ABC) transporters (drug efflux pumps), and promotion of cancer stem cells. There is also evidence that PRE promotes cancer drug resistance by way of upregulating ABC transporters [11] and promoting cancer stem-like properties [12].
[0013] Pegvisomant has been shown to reverse the GH stimulated resistance of breast cancer cells in vitro to the drug doxorubicin in cell proliferation studies [13]. Pegvisomant has also been shown to reverse GH promoted resistance to doxorubicin induced apoptosis
[14] in a cell culture assays. A novel GHR antagonist (referred to herein as "Compound G") has been prepared that binds to the GHR more tightly than pegvisomant (see US Patent No.
10,874,717, which is incorporated by reference herein in its entirety). Unlike pegvisomant, Compound G also binds tightly to the PRLR (see U.S. Patent Application No. 16/903,644, which is incorporated by reference herein in its entirety). The ability of Compound G to reverse GH
stimulated drug resistance both in vitro and in vivo is described herein.
SUMMARY
[0014] The following provides a summary of certain example implementations of the disclosed inventive subject matter. This summary is not an extensive overview and is not intended to identify key or critical aspects or elements of the disclosed inventive subject matter or to delineate its scope. However, it is to be understood that the use of indefinite articles in the language used to describe and claim the disclosed inventive subject matter is not intended in any way to limit the described inventive subject matter. Rather the use of "a" or "an"
should be interpreted to mean "at least one" or "one or more".
10,874,717, which is incorporated by reference herein in its entirety). Unlike pegvisomant, Compound G also binds tightly to the PRLR (see U.S. Patent Application No. 16/903,644, which is incorporated by reference herein in its entirety). The ability of Compound G to reverse GH
stimulated drug resistance both in vitro and in vivo is described herein.
SUMMARY
[0014] The following provides a summary of certain example implementations of the disclosed inventive subject matter. This summary is not an extensive overview and is not intended to identify key or critical aspects or elements of the disclosed inventive subject matter or to delineate its scope. However, it is to be understood that the use of indefinite articles in the language used to describe and claim the disclosed inventive subject matter is not intended in any way to limit the described inventive subject matter. Rather the use of "a" or "an"
should be interpreted to mean "at least one" or "one or more".
[0015] One implementation of the disclosed technology provides a composition and method for treating a disease or condition responsive to human growth hormone receptor antagonists. The composition comprises a modified human growth hormone receptor antagonist, and an anti-cancer composition. The method for treating diseases or conditions responsive to human growth hormone receptor antagonists, comprises administering to a patient an effective amount of the composition. The disease or condition responsive to human growth hormone receptor antagonists may be a cancer that expresses predetermined levels of growth hormone receptor (GHR); predetermined levels of prolactin receptor (PRLR);
predetermined levels of both GHR and PRLR); predetermined levels of ATP-binding cassette (ABC)-transporters; or predetermined levels of epithelial to mesenchymal transition (EMT) mediators.
The disease or condition responsive to human growth hormone receptor antagonists may be breast cancer, central nervous system cancer, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, renal cancer, pancreatic cancer, endometrial cancer, meningioma, colorectal cancer, colon cancer, neuroblastoma, stomach cancer, liver cancer, lymphoma, combinations thereof, or any other cancer expressing predetermined amounts of GHR, PRLR, ABC transporters, EMT
mediators, or combinations thereof.
predetermined levels of both GHR and PRLR); predetermined levels of ATP-binding cassette (ABC)-transporters; or predetermined levels of epithelial to mesenchymal transition (EMT) mediators.
The disease or condition responsive to human growth hormone receptor antagonists may be breast cancer, central nervous system cancer, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, renal cancer, pancreatic cancer, endometrial cancer, meningioma, colorectal cancer, colon cancer, neuroblastoma, stomach cancer, liver cancer, lymphoma, combinations thereof, or any other cancer expressing predetermined amounts of GHR, PRLR, ABC transporters, EMT
mediators, or combinations thereof.
[0016] The modified human growth hormone receptor antagonist may comprise human growth hormone receptor antagonist G120K wherein two amino acids of human growth hormone receptor antagonist G120K have been changed to cysteine, wherein the two amino acids changed to cysteine are T142 and H151; and a polyethylene glycol molecule conjugated to each substituted cysteine in the human growth hormone receptor antagonist G120K-T151C-T142C, wherein the polyethylene glycol molecules conjugated to the two amino acids changed to cysteine are two 4.5 kDa branched polyethylene glycols each containing three carboxylate anions.
The human growth hormone receptor antagonist G120K may have a DNA sequence of SEQ ID NO: 1 and an amino acid sequence of SEQ ID NO: 2. The human growth hormone receptor antagonist T142C may have a DNA sequence of SEQ ID NO: 3 and an amino acid sequence of SEQ ID NO:
4. The following amino acid substitutions may be made: H18D, H21N, R167N, K168A, D171S, K172R, E174S, and I179T for preventing binding to a prolactin receptor and this modified composition may be adapted and used for the treatment of acromegaly. The polyethylene glycol molecule may be prepared by stepwise organic chemistry and may be a substantially pure single compound, and the polyethylene glycol molecule may be a branched structure.
The polyethylene glycol molecule may contain a maleimide group for conjugation to a free sulfhydryl group.
The human growth hormone receptor antagonist G120K may have a DNA sequence of SEQ ID NO: 1 and an amino acid sequence of SEQ ID NO: 2. The human growth hormone receptor antagonist T142C may have a DNA sequence of SEQ ID NO: 3 and an amino acid sequence of SEQ ID NO:
4. The following amino acid substitutions may be made: H18D, H21N, R167N, K168A, D171S, K172R, E174S, and I179T for preventing binding to a prolactin receptor and this modified composition may be adapted and used for the treatment of acromegaly. The polyethylene glycol molecule may be prepared by stepwise organic chemistry and may be a substantially pure single compound, and the polyethylene glycol molecule may be a branched structure.
The polyethylene glycol molecule may contain a maleimide group for conjugation to a free sulfhydryl group.
[0017] The anti-cancer composition may be an alkylating agent; an antimetabolite; a plant alkaloid; an antitumor antibiotic; or combinations thereof. The alkylating agent may be chlorambucil, cyclophosphamide, thiotepa, busulfan, cisplatin, or combinations thereof. The antimetabolite may be gemcitabine, 5-fluorouracil, 6-mercaptopurine, cytarabine, or combinations thereof. The plant alkaloid may be vincristine, paclitaxel, etoposide, irinotecan, or combinations thereof. The antitumor antibiotic may be doxorubicin, dactinomycin, mitoxantrone, idarubicin, or combinations thereof The anti-cancer composition may be a targeted therapy that includes vemurafenib or similar drugs.
[0018] Another implementation of the disclosed technology provides another composition and method for treating a disease or condition responsive to human growth hormone receptor antagonists. The composition comprises a modified human growth hormone receptor antagonist, wherein the human growth hormone receptor antagonist comprises human growth hormone receptor antagonist G120K wherein two amino acids of human growth hormone receptor antagonist G120K have been changed to cysteine, wherein the two amino acids changed to cysteine are T142 and H151; and a polyethylene glycol molecule conjugated to each substituted cysteine in the human growth hormone receptor antagonist G120K-H151C-T142C, wherein the polyethylene glycol molecules conjugated to the two amino acids changed to cysteine are two 4.5 kDa branched polyethylene glycols each containing three carboxylate anions, wherein the polyethylene glycol molecule is prepared by step-wise organic chemistry and is a substantially pure single compound, and wherein the polyethylene glycol molecule is a branched structure; and an anti-cancer composition. The method for treating diseases or conditions responsive to human growth hormone receptor antagonists, comprises administering to a patient an effective amount of the composition.
[0019] The disease or condition responsive to human growth hormone receptor antagonists may be a cancer that expresses predetermined levels of growth hormone receptor (GHR);
predetermined levels of prolactin receptor (PRLR); predetermined levels of both GHR and PRLR);
predetermined levels of ATP-binding cassette (ABC)-transporters; or predetermined levels of epithelial to mesenchymal transition (EMT) mediators. The disease or condition responsive to human growth hormone receptor antagonists may be breast cancer, central nervous system cancer, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, renal cancer, pancreatic cancer, endometrial cancer, meningioma, colorectal cancer, colon cancer, neuroblastoma, stomach cancer, liver cancer, lymphoma, combinations thereof, or any other cancer expressing predetermined amounts of GHR, PRLR, ABC transporters, EMT mediators, or combinations thereof. The human growth hormone receptor antagonist G120K may have a DNA
sequence of SEQ ID NO: 1 and an amino acid sequence of SEQ ID NO: 2. The human growth hormone receptor antagonist G120K-H151C-T142C may have a DNA sequence of SEQ ID NO: 3 and an amino acid sequence of SEQ ID NO: 4. The following amino acid substitutions may be made:
H18D, H21N, R167N, K168A, D1715, K172R, E1745, and I179T for preventing binding to a prolactin receptor and this modified composition may be adapted and used for the treatment of acromegaly. The polyethylene glycol molecule may contain a maleimide group for conjugation to a free sulfhydryl group.
predetermined levels of prolactin receptor (PRLR); predetermined levels of both GHR and PRLR);
predetermined levels of ATP-binding cassette (ABC)-transporters; or predetermined levels of epithelial to mesenchymal transition (EMT) mediators. The disease or condition responsive to human growth hormone receptor antagonists may be breast cancer, central nervous system cancer, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, renal cancer, pancreatic cancer, endometrial cancer, meningioma, colorectal cancer, colon cancer, neuroblastoma, stomach cancer, liver cancer, lymphoma, combinations thereof, or any other cancer expressing predetermined amounts of GHR, PRLR, ABC transporters, EMT mediators, or combinations thereof. The human growth hormone receptor antagonist G120K may have a DNA
sequence of SEQ ID NO: 1 and an amino acid sequence of SEQ ID NO: 2. The human growth hormone receptor antagonist G120K-H151C-T142C may have a DNA sequence of SEQ ID NO: 3 and an amino acid sequence of SEQ ID NO: 4. The following amino acid substitutions may be made:
H18D, H21N, R167N, K168A, D1715, K172R, E1745, and I179T for preventing binding to a prolactin receptor and this modified composition may be adapted and used for the treatment of acromegaly. The polyethylene glycol molecule may contain a maleimide group for conjugation to a free sulfhydryl group.
[0020] The anti-cancer composition may be an alkylating agent; an antimetabolite; a plant alkaloid; an antitumor antibiotic; or combinations thereof. The alkylating agent may be chlorambucil, cyclophosphamide, thiotepa, busulfan, cisplatin, or combinations thereof. The antimetabolite may be gemcitabine, 5-fluorouracil, 6-mercaptopurine, cytarabine, or combinations thereof. The plant alkaloid may be vincristine, paclitaxel, etoposide, irinotecan, or combinations thereof. The antitumor antibiotic may be doxorubicin, dactinomycin, mitoxantrone, idarubicin, or combinations thereof The anti-cancer composition may be a targeted therapy that includes vemurafenib or similar drugs.
[0021] Still another implementation of the disclosed technology provides a method for treating cancer using human growth hormone antagonists, comprising pre-screening a patient by analyzing a tumor biopsy to confirm the presence of cancer and the presence of certain predetermined factors indicative of responsiveness to human growth hormone antagonists; and treating the patient with an effective amount of a composition that includes a modified human growth hormone receptor antagonist and an anti-cancer composition. The certain predetermined factors may include the predetermined levels of GHR, PRLR, ABC transporters, EMT mediators, insulin-like growth factor-1 (IGF-1); IFG binding protein-3 (IGFBP3), suppressor of cytokine signaling (SOCS -1, -2, -3; and cytokine inducible 5H2 containing protein (CISH). The cancer may be breast cancer, central nervous system cancer, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, renal cancer, pancreatic cancer, endometrial cancer, meningioma, colorectal cancer, colon cancer, neuroblastoma, stomach cancer, liver cancer, lymphoma, combinations thereof, or any other cancer expressing predetermined amounts of the predetermined factors.
[0022] The modified human growth hormone receptor antagonist may comprise human growth hormone receptor antagonist G120K wherein two amino acids of human growth hormone receptor antagonist G120K have been changed to cysteine, wherein the two amino acids changed to cysteine are T142 and H151; and a polyethylene glycol molecule conjugated to each substituted cysteine in the human growth hormone receptor antagonist G120K-H151C-T142C, wherein the polyethylene glycol molecules conjugated to the two amino acids changed to cysteine are two 4.5 kDa branched polyethylene glycols each containing three carboxylate anions.
The human growth hormone receptor antagonist G120K may have a DNA sequence of SEQ ID NO: 1 and an amino acid sequence of SEQ ID NO: 2. The human growth hormone receptor antagonist T142C may have a DNA sequence of SEQ ID NO: 3 and an amino acid sequence of SEQ ID NO:
4. The polyethylene glycol molecule may be prepared by step-wise organic chemistry and may be a substantially pure single compound, and the polyethylene glycol molecule may be a branched structure. The polyethylene glycol molecule may contain a maleimide group for conjugation to a free sulfhydryl group.
The human growth hormone receptor antagonist G120K may have a DNA sequence of SEQ ID NO: 1 and an amino acid sequence of SEQ ID NO: 2. The human growth hormone receptor antagonist T142C may have a DNA sequence of SEQ ID NO: 3 and an amino acid sequence of SEQ ID NO:
4. The polyethylene glycol molecule may be prepared by step-wise organic chemistry and may be a substantially pure single compound, and the polyethylene glycol molecule may be a branched structure. The polyethylene glycol molecule may contain a maleimide group for conjugation to a free sulfhydryl group.
[0023] The anti-cancer composition may be an alkylating agent; an antimetabolite; a plant alkaloid; an antitumor antibiotic; or combinations thereof. The alkylating agent may be chlorambucil, cyclophosphamide, thiotepa, busulfan, cisplatin, or combinations thereof. The antimetabolite may be gemcitabine, 5-fluorouracil, 6-mercaptopurine, cytarabine, or combinations thereof. The plant alkaloid may be vincristine, paclitaxel, etoposide, irinotecan, or combinations thereof. The antitumor antibiotic may be doxorubicin, dactinomycin, mitoxantrone, idarubicin, or combinations thereof The anti-cancer composition may be a targeted therapy that includes vemurafenib or similar drugs.
BRIEF DESCRIPTION OF THE DRAWINGS
BRIEF DESCRIPTION OF THE DRAWINGS
[0024] The patent or application file contains at least one drawing executed in color.
Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0025] The accompanying figures, which are incorporated into and form a part of the specification, schematically illustrate one or more example implementations of the disclosed inventive subject matter and, together with the general description given above and detailed description given below, serve to explain the principles of the disclosed subject matter, and wherein:
[0026] FIG. 1 is a bar chart depicting the level of GHR mRNA expression in multiple cell lines from thirty-seven (37) cancer cell types, which are listed along the x-axis of the chart;
[0027] FIGS. 2A-2C are plots for two breast cancer subtypes (triple-negative and HER2-enriched breast cancers) showing the differences in patient overall survival (in months) for cancers with low and high growth hormone receptor (GHR) expression levels, wherein FIG. 2A includes data for subtype HER2 enriched (ER-PR-RER+) breast cancer (n=96), wherein FIG.
2B includes data for subtype triple-negative breast cancer (n=405), and wherein FIG. 2C
includes data for subtype triple-negative breast cancer / chemotherapy-treated (n=227);
2B includes data for subtype triple-negative breast cancer (n=405), and wherein FIG. 2C
includes data for subtype triple-negative breast cancer / chemotherapy-treated (n=227);
[0028] FIGS. 3A-3D are graphs showing the relationship between overall survival for breast cancer (BC) patients (ungrouped/all) with specific gene expression in the Cancer Genome Atlas (TCGA) breast cancer database, wherein data for patients with high GHR
expression (FIG.
3A) or high PRLR expression (FIG. 3B) had a poorer survival compared to low GHR or low PRLR
expression groups, and wherein in breast cancer patients with high expression of both GHR and PRLR (FIG. 3C), or with high expression of GH,GHR, and PRLR (FIG. 3D), survival was significantly poorer than the corresponding low expression cohorts of the same gene-sets (processed using GEPIA2);
expression (FIG.
3A) or high PRLR expression (FIG. 3B) had a poorer survival compared to low GHR or low PRLR
expression groups, and wherein in breast cancer patients with high expression of both GHR and PRLR (FIG. 3C), or with high expression of GH,GHR, and PRLR (FIG. 3D), survival was significantly poorer than the corresponding low expression cohorts of the same gene-sets (processed using GEPIA2);
[0029] FIG. 4A is a heatmap showing a Spearman correlation coefficient between GHR
expression and ABC type multidrug transporter expression across forty (40) different cancer types from human patients in The Cancer Genome Atlas (TCGA) database, wherein the heatmap indicates a consistent positive (red) correlation between GHR expression and ABC type multidrug transporters.
expression and ABC type multidrug transporter expression across forty (40) different cancer types from human patients in The Cancer Genome Atlas (TCGA) database, wherein the heatmap indicates a consistent positive (red) correlation between GHR expression and ABC type multidrug transporters.
[0030] FIG. 4B is a heatmap showing a Spearman correlation coefficient between GHR
expression and known EMT markers expression across forty (40) different cancer types from human patients in the TCGA database, wherein the heatmap indicates a consistent positive (red) correlation between GHR and markers of EMT across majority of cancer types.
expression and known EMT markers expression across forty (40) different cancer types from human patients in the TCGA database, wherein the heatmap indicates a consistent positive (red) correlation between GHR and markers of EMT across majority of cancer types.
[0031] FIGS. 5A(1)-5A(6) show the effect of GHR antagonists on the expression of six ABC transporters in a melanoma cell line, wherein FIG. 5A(1) includes data for MALME-3M ¨
ABCB1, FIG. 5A(2) includes data for MALME-3M ¨ ABCB8, FIG. 5A(3) includes data for MALME-3M ¨ ABCC-1, FIG. 5A(4) includes data for MALME-3M ¨ ABCC2, FIG. 5A(5) includes data for MALME-3M ¨ ABCG1, and FIG. 5A(6) includes data for MALME-3M
¨
ABCG2;
ABCB1, FIG. 5A(2) includes data for MALME-3M ¨ ABCB8, FIG. 5A(3) includes data for MALME-3M ¨ ABCC-1, FIG. 5A(4) includes data for MALME-3M ¨ ABCC2, FIG. 5A(5) includes data for MALME-3M ¨ ABCG1, and FIG. 5A(6) includes data for MALME-3M
¨
ABCG2;
[0032] FIGS. 5B(1)-5B(9) show the effect of GHR antagonists on the expression of nine EMT markers in a melanoma cell line, wherein FIG. 5B(1) includes data for MALME-3M ¨
FGFBP1, FIG. 5B(2) includes data for MALME-3M ¨ CDH1, FIG. 5B(3) includes data for MALME-3M ¨ CLDN1, FIG. 5B(4) includes data for MALME-3M ¨ ZEB1, FIG. 5B(5) includes data for MALME-3M ¨ CDH2, FIG. 5B(6) includes data for MALME-3M ¨ EPAS1, FIG.
5B(7) includes data for MALME-3M ¨ SNAIL FIG. 5B(8) includes data for MALME-3M ¨
SNAI2, and FIG. 5B(9) includes data for MALME-3M ¨ VIM;
FGFBP1, FIG. 5B(2) includes data for MALME-3M ¨ CDH1, FIG. 5B(3) includes data for MALME-3M ¨ CLDN1, FIG. 5B(4) includes data for MALME-3M ¨ ZEB1, FIG. 5B(5) includes data for MALME-3M ¨ CDH2, FIG. 5B(6) includes data for MALME-3M ¨ EPAS1, FIG.
5B(7) includes data for MALME-3M ¨ SNAIL FIG. 5B(8) includes data for MALME-3M ¨
SNAI2, and FIG. 5B(9) includes data for MALME-3M ¨ VIM;
[0033] FIGS. 6A-6D show the effect of GHR antagonists (Peg=pegvisomant, G=
Compound G) on a basement membrane invasion assay (in vitro) (FIG. 6A) using three pancreatic cancer cell lines (n=3, * indicates p < 0.05), wherein GH increases the tumor cell invasion rate while the GHR antagonists significantly suppress it, and wherein FIG. 6B
includes data for invasion assay ¨ BxPC3, FIG. 6C includes data for invasion assay ¨ PANC1, and FIG. 6B includes data for invasion assay ¨ LTPA;
Compound G) on a basement membrane invasion assay (in vitro) (FIG. 6A) using three pancreatic cancer cell lines (n=3, * indicates p < 0.05), wherein GH increases the tumor cell invasion rate while the GHR antagonists significantly suppress it, and wherein FIG. 6B
includes data for invasion assay ¨ BxPC3, FIG. 6C includes data for invasion assay ¨ PANC1, and FIG. 6B includes data for invasion assay ¨ LTPA;
[0034] FIGS. 7A, 7B, and 7C(1)-7C(8) show the effect of GHR antagonists [Peg=pegvisomant, G=Compound G] on drug efflux rate (FIG. 7A), percentage of drug retention (FG. FIG. 7B), and fluorescent images after a fluorescent drug surrogate (Di0C2) has been loaded into pancreatic cancer cells using an in vitro multidrug efflux assay method (n=3, * indicates p <
0.05) (FIGS. 7C(1)-7C(8)), wherein GH increases the tumor cell drug efflux rate (decreases drug retention in tumor cells) while the GHR antagonists significantly suppress it;
0.05) (FIGS. 7C(1)-7C(8)), wherein GH increases the tumor cell drug efflux rate (decreases drug retention in tumor cells) while the GHR antagonists significantly suppress it;
[0035] FIG. 8 shows the viability of pancreatic cancer cells when incubated in the presence anti-cancer drugs and either PBS, GH, GH + pegvisomant, or GH + Compound G, wherein the anti-cancer drugs used were doxorubicin (doxo), erlotinib (erlo), or gemcitabine (gemc), and the control was DMSO;
[0036] FIG. 9A is a graph showing the effect of different treatments on the growth (tumor volume) of human pancreatic cancer (PANC1) xenografts implanted in male nude mice, wherein the hGHR antagonists were pegvisomant (peg) and compound-G (G) treated at 10 mg/kg/day while gem20 = gemcitabine was treated at 20 mg/kg every 3 days, wherein all treatments started at day-17 and were by intra-peritoneal injections, and wherein gemcitabine, pegvisomant, or compound-G by themselves were effective in decreasing tumor growth rate when used as monotherapy;
however, combinations of gem20 + peg or gem20 + G were significantly more efficacious than gem20 or peg or G alone;
however, combinations of gem20 + peg or gem20 + G were significantly more efficacious than gem20 or peg or G alone;
[0037] FIG. 9B is a graph showing the effect of different treatments on the growth (tumor volume) of human pancreatic cancer (PANC1) xenografts implanted in male nude mice, wherein the hGHR antagonist was compound-G (G) treated at 10 mg/kg/day while gem20 =
gemcitabine was treated at 20 mg/kg every 3 days, or gem80 = gemcitabine was treated at 80 mg/kg every 3 days, wherein all treatments started at day 17 and were by intra-peritoneal injections, wherein both doses of gemcitabine or compound-G were effective in decreasing tumor growth rate when used as monotherapy; however, combinations of gem20+G or gem80+G were significantly more efficacious than gem20 or gem80 or G alone, and wherein Gem20+G was more efficacious than Gem20, while Gem80+G was more efficacious than Gem80 alone and Gem20+G was better than Gem80 alone; and
gemcitabine was treated at 20 mg/kg every 3 days, or gem80 = gemcitabine was treated at 80 mg/kg every 3 days, wherein all treatments started at day 17 and were by intra-peritoneal injections, wherein both doses of gemcitabine or compound-G were effective in decreasing tumor growth rate when used as monotherapy; however, combinations of gem20+G or gem80+G were significantly more efficacious than gem20 or gem80 or G alone, and wherein Gem20+G was more efficacious than Gem20, while Gem80+G was more efficacious than Gem80 alone and Gem20+G was better than Gem80 alone; and
[0038] FIG. 10 is a graph showing the effect of different treatments on the growth (tumor volume) of human pancreatic cancer (PANC1) xenografts implanted in female nude mice, wherein the hGHR antagonist is compound-G (G) treated at 10 mg/kg/day while gem20 =
gemcitabine treated at 20 mg/kg every 3 days or gem80 = gemcitabine treated at 80 mg/kg every 3 days, wherein all treatments started at day-17 and were by intra-peritoneal injections, and wherein both doses of gemcitabine or compound-G were effective in decreasing tumor growth rate when used as monotherapy; however, combinations of gem20+G or gem80+G were significantly more efficacious than gem20 or gem80 or G alone, wherein Gem20+G was more efficacious than Gem20 while Gem80+G was more efficacious than Gem80 alone and Gem20+G was as efficacious as Gem80 alone.
DE TAILED DESCRIPTION
gemcitabine treated at 20 mg/kg every 3 days or gem80 = gemcitabine treated at 80 mg/kg every 3 days, wherein all treatments started at day-17 and were by intra-peritoneal injections, and wherein both doses of gemcitabine or compound-G were effective in decreasing tumor growth rate when used as monotherapy; however, combinations of gem20+G or gem80+G were significantly more efficacious than gem20 or gem80 or G alone, wherein Gem20+G was more efficacious than Gem20 while Gem80+G was more efficacious than Gem80 alone and Gem20+G was as efficacious as Gem80 alone.
DE TAILED DESCRIPTION
[0039] Example implementations are now described with reference to the Figures.
Reference numerals are used throughout the detailed description to refer to the various elements and structures. Although the following detailed description contains many specifics for the purposes of illustration, a person of ordinary skill in the art will appreciate that many variations and alterations to the following details are within the scope of the disclosed inventive subject matter. Accordingly, the following implementations are set forth without any loss of generality to, and without imposing limitations upon, the claimed subject matter.
Reference numerals are used throughout the detailed description to refer to the various elements and structures. Although the following detailed description contains many specifics for the purposes of illustration, a person of ordinary skill in the art will appreciate that many variations and alterations to the following details are within the scope of the disclosed inventive subject matter. Accordingly, the following implementations are set forth without any loss of generality to, and without imposing limitations upon, the claimed subject matter.
[0040] The following abbreviations, which are used throughout this application, have the following specific meanings. dPEG -A refers to MAL-dPEG 12-Tris(-dPEG 24-acid)3 (Quanta BioDesign #1145). Compound G or G refers to hGHR antagonist hGH-G120K having T142 and H151 changed to cysteine and having both added cysteines conjugated with dPEG -A. Compound D or D refers to hGHR antagonist hGH-G120K having T142 changed to cysteine and having the added cysteine conjugated with a 40 kDa branched polyethylene glycol. Peg refers to pegvisomant and Dox refers to doxorubicin. The disclosed technology includes compositions and methods for treating cancer patients who are identified by expression of GHR, PRLR, selected ABC drug efflux pumps, selected EMT modulators, IGF-1, IGFBP3, SOCS-1, or CISH., wherein treatment comprises administering to the patient an effective dose of a chemotherapeutic drug combined with an effective dose of Compound G.
GHR Expression in Cancer Cell Lines
GHR Expression in Cancer Cell Lines
[0041] The effectiveness of an hGHR antagonist for cancer treatment, either by itself or in combination with a cancer drug, is related closely to the expression of the hGHR by a particular cancer. When the hGHR antagonist is also an antagonist of the PRLR, then the level of PRLR
expression will also determine the susceptibility of a cancer to this treatment. It was previously observed that most of 60 cell lines from nine cancer types expressed high levels of either the hGHR, the PRLR, or both receptors [5]. Analysis of the levels of GHR mRNA
expression from 37 cancer types (see FIG. 1), with between 4 and 131 cell lines included for each cancer, indicated that almost all of the cancer types had high hGHR expression for at least a subset of the individual cancers tested.
expression will also determine the susceptibility of a cancer to this treatment. It was previously observed that most of 60 cell lines from nine cancer types expressed high levels of either the hGHR, the PRLR, or both receptors [5]. Analysis of the levels of GHR mRNA
expression from 37 cancer types (see FIG. 1), with between 4 and 131 cell lines included for each cancer, indicated that almost all of the cancer types had high hGHR expression for at least a subset of the individual cancers tested.
[0042] The level of hGHR expression across multiple human patient datasets correlates with decreased patient survival for HER2 enriched breast cancer and triple-negative breast cancer (see FIGS. 2A-2C). FIGS. 3A-3D illustrate that breast cancer patients with increased levels of both GHR + PRLR expression or GH+GHR+PRLR expression have lower percent survivals than high levels of GH or GHR or PRLR expression alone.
GHR Expression and the Expression of ABC transporters and EMT Markers
GHR Expression and the Expression of ABC transporters and EMT Markers
[0043] FIG. 4A shows a correlation across 40 different cancer cell types between GHR
expression and the expression of ABC transporters across all patients in the TCGA database. FIG.
4B shows the same correlation between GHR expression and the expression of EMT
mediators.
Because upregulation of ABC transporters and EMT mediators lead to chemotherapy resistance, these Figures shows that chemotherapy resistance is associated with GHR
expression.
expression and the expression of ABC transporters across all patients in the TCGA database. FIG.
4B shows the same correlation between GHR expression and the expression of EMT
mediators.
Because upregulation of ABC transporters and EMT mediators lead to chemotherapy resistance, these Figures shows that chemotherapy resistance is associated with GHR
expression.
[0044] The effect of GHR antagonists on the expression of six ABC
transporters in a melanoma cell line is shown in FIGS. 5A(1)-5A(6). When used as a monotherapy, Compound G
significantly reduces the expression of four of the six ABC transporters. When GH or doxorubicin is present, Compound G also reduces the expression of four ABC transporters.
When both GH and doxorubicin are added, Compound G greatly reduces the expression of all six ABC transporters.
This observation is due to the fact that the expression of ABC transporters is enhanced in presence of GH or doxorubicin or both GH and doxorubicin.
transporters in a melanoma cell line is shown in FIGS. 5A(1)-5A(6). When used as a monotherapy, Compound G
significantly reduces the expression of four of the six ABC transporters. When GH or doxorubicin is present, Compound G also reduces the expression of four ABC transporters.
When both GH and doxorubicin are added, Compound G greatly reduces the expression of all six ABC transporters.
This observation is due to the fact that the expression of ABC transporters is enhanced in presence of GH or doxorubicin or both GH and doxorubicin.
[0045] The effect of hGHR antagonists on the expression of nine EMT
markers in a melanoma cell line is shown in FIGS. 5B(1)-5B(9). When used as a monotherapy, Compound G
significantly reduces the expression of multiple EMT mediators. When GH or doxorubicin or both are present, Compound G also reduces the expression of multiple EMT mediators, presumably because the expression of EMT mediators is significantly enhanced in presence of GH or doxorubicin or both GH and doxorubicin.
markers in a melanoma cell line is shown in FIGS. 5B(1)-5B(9). When used as a monotherapy, Compound G
significantly reduces the expression of multiple EMT mediators. When GH or doxorubicin or both are present, Compound G also reduces the expression of multiple EMT mediators, presumably because the expression of EMT mediators is significantly enhanced in presence of GH or doxorubicin or both GH and doxorubicin.
[0046] FIGS. 6A-6D show the effect of the hGHR antagonists Compound G and pegvisomant on a basement membrane invasion assay using three pancreatic cancer cell lines. This assay quantifies the ability of cells to migrate through a membrane, a property of cells that have transitioned from epithelial cells to mesenchymal cells. For all three cell lines, the addition of GH
increases cell migration. This effect of GH is blocked by the addition of either pegvisomant or Compound G.
The Effect of hGHR Antagonists on Drug Efflux
increases cell migration. This effect of GH is blocked by the addition of either pegvisomant or Compound G.
The Effect of hGHR Antagonists on Drug Efflux
[0047] The effect of hGHR antagonists on the drug efflux rate, using Di0C2 dye as a drug surrogate, from pancreatic cancer cells is shown in FIGS. 7A-7C. With reference to FIG. 7A, after 120 minutes, the efflux rate with GH addition is approximately four-fold greater than the efflux rate with no additives (PBS). In the presence of GH + Pegvisomant or GH +
Compound G, the efflux rate is markedly suppressed compared with GH alone by a factor of approximately two.
FIG. 7B, illustrates the effect of hGHR antagonists on the percentage of drug retention from pancreatic cancer cells. In the PBS control, approximately 85% of the drug is retained after 120 minutes. The retention after 120 minutes decreases to ¨54% in the presence of GH but increases to ¨83% in the presence of GH plus Compound G or GH plus Pegvisomant. Finally, FIGS. 7C(1)-7C(8) provides fluorescent images of a labeled drug after being loaded into pancreatic cancer cells and incubated for 0 minutes and 120 minutes in PBS (FIG.7C(1)-FIG.7C(2)), GH
(FIG.7C(3)-FIG.7C(4)), GH + Pegvisomant (FIG.7C(5)-FIG.7C(6)), or GH + Compound G
(FIG.7C(7)-FIG.7C(8)). In FIGS. 7C(1)-7C(8), the fluorescence of the cells at 0 minutes is different for the four different conditions, so the drug remaining after 120 minutes (fluorescence) was compared with its own 0 min control. It is clear from the images that the cells treated with GH + Compound G retain the greatest amount of drug.
Compound G, the efflux rate is markedly suppressed compared with GH alone by a factor of approximately two.
FIG. 7B, illustrates the effect of hGHR antagonists on the percentage of drug retention from pancreatic cancer cells. In the PBS control, approximately 85% of the drug is retained after 120 minutes. The retention after 120 minutes decreases to ¨54% in the presence of GH but increases to ¨83% in the presence of GH plus Compound G or GH plus Pegvisomant. Finally, FIGS. 7C(1)-7C(8) provides fluorescent images of a labeled drug after being loaded into pancreatic cancer cells and incubated for 0 minutes and 120 minutes in PBS (FIG.7C(1)-FIG.7C(2)), GH
(FIG.7C(3)-FIG.7C(4)), GH + Pegvisomant (FIG.7C(5)-FIG.7C(6)), or GH + Compound G
(FIG.7C(7)-FIG.7C(8)). In FIGS. 7C(1)-7C(8), the fluorescence of the cells at 0 minutes is different for the four different conditions, so the drug remaining after 120 minutes (fluorescence) was compared with its own 0 min control. It is clear from the images that the cells treated with GH + Compound G retain the greatest amount of drug.
[0048] FIG. 8 illustrates the viability of pancreatic cancer cells when incubated in the presence of anti-cancer drugs and either buffer (PBS), GH, GH + Pegvisomant, or GH +
Compound G. The anti-cancer drugs are doxorubicin (doxo), erlotnib (erlo), or gemcitabine (gemc) and the control is DMSO, the vehicle for the anti-cancer drugs. In all cases, the addition of GH
increases the cell viability. However, the addition of either Pegvisomant or Compound G to the GH reduces the viability, in all cases, to below that of PBS.
The Effect of GHR Antagonists + Anti-Cancer Drugs on Pancreatic Tumor Xenografts
Compound G. The anti-cancer drugs are doxorubicin (doxo), erlotnib (erlo), or gemcitabine (gemc) and the control is DMSO, the vehicle for the anti-cancer drugs. In all cases, the addition of GH
increases the cell viability. However, the addition of either Pegvisomant or Compound G to the GH reduces the viability, in all cases, to below that of PBS.
The Effect of GHR Antagonists + Anti-Cancer Drugs on Pancreatic Tumor Xenografts
[0049] Specific volumes of pancreatic tumor xenografts implanted in male nude mice after treatment with hGHR antagonists (10 mg/kg/day), gemcitabine (20 mg/kg/3-days) and combinations of the antagonists + gemcitabine are shown in FIG. 9A. Treatments started at day-17. Both of the hGHR antagonists (pegvisomant and Compound G) significantly decrease the tumor volume relative to that of the PBS control by day-30 (13 days after start of treatment).
However, for both of these antagonists, the tumor volume continues to increase. Gemcitabine alone shows a greater reduction of tumor volume compared to the hGHR antagonists, but the absolute tumor volume appears to resume trending upwards by day-43. The combinations of gemcitabine + pegvisomant and gemcitabine + Compound G show the greatest reduction of tumor volume.
After day-43 (26 days of treatment) there is no indication that the tumor volume has begun to increase using the combination treatments. The combination of Compound G +
gemcitabine gave the greatest tumor volume reduction.
However, for both of these antagonists, the tumor volume continues to increase. Gemcitabine alone shows a greater reduction of tumor volume compared to the hGHR antagonists, but the absolute tumor volume appears to resume trending upwards by day-43. The combinations of gemcitabine + pegvisomant and gemcitabine + Compound G show the greatest reduction of tumor volume.
After day-43 (26 days of treatment) there is no indication that the tumor volume has begun to increase using the combination treatments. The combination of Compound G +
gemcitabine gave the greatest tumor volume reduction.
[0050] FIG. 9B shows the volume of pancreatic tumor xenografts implanted in male nude mice after treatment with 80 mg/kg/3-days gemcitabine and Compound G (10 mg/kg/day) + 80 mg/kg/3-days gemcitabine. The plots for PBS, Compound G (10 mg/kg/day) alone, gemcitabine (20 mg/kg/3-days) alone, or Compound G (10 mg/kg/day) + gemcitabine (20 mg/kg/3-days), which are taken from Figure 9A, are also included in Figure 9B. Gemcitabine by itself at 80 mg/kg/3-days does not decrease the tumor volume significantly beyond that obtained with 20 mg/kg/3-day dose of the same drug and, for the 80 mg/kg/3-day regimen, the tumor volume appears to have plateaued by day-43 (26 days of treatment). The 80 mg/kg/3-days Gemcitabine +
mg/kg/day Compound G caused the maximum tumor volume reduction of all conditions, and the tumor volume appears to be still decreasing at the final day of the study (day-43).
mg/kg/day Compound G caused the maximum tumor volume reduction of all conditions, and the tumor volume appears to be still decreasing at the final day of the study (day-43).
[0051] FIG. 10 shows the volume of pancreatic tumor xenografts implanted in female nude mice after treatment with either Compound-G (10 mg/kg/day) alone, or gemcitabine (20 or 80 mg/kg/3-days) alone, or Compound G (10 mg/kg/day) + 20 mg/kg/3-days gemcitabine, or Compound G (10 mg/kg/day) + 80 mg/kg/3-days gemcitabine. Treatment started at day-17. After 25 days of treatment (day-42 of study), the tumor reduction due to 20 mg/kg/3-days gemcitabine alone or Compound G (10 mg/kg/day) alone are almost equivalent but only the gemcitabine treated mice show tumor volumes that are trending higher, indicating onset of chemoresistance. The combination of Compound G (10 mg/kg/day) + 20 mg/kg/3-days gemcitabine reduces the tumor volume growth drastically and the tumor volume does not appear to trend upwards through the end of the study (day-44). Gemcitabine at 80 mg/kg/3-days alone shows the same tumor reduction at day-44 as Compound G (10 mg/kg/day) + 20 mg/kg/3-days gemcitabine. Compound G
(10 mg/kg/day) + 80 mg/kg/3-days gemcitabine shows the greatest inhibition of tumor growth, which appears to be still decreasing after 44 days (end of study), at which point 3 of 8 animals in the group were tumor-free.
Personalized Medicine/Precision Medicine Preliminary Diagnostic Test
(10 mg/kg/day) + 80 mg/kg/3-days gemcitabine shows the greatest inhibition of tumor growth, which appears to be still decreasing after 44 days (end of study), at which point 3 of 8 animals in the group were tumor-free.
Personalized Medicine/Precision Medicine Preliminary Diagnostic Test
[0052] One implementation of the disclosed technology includes a preliminary molecular analysis of a tumor biopsy sample to determine if a patient is a suitable candidate for treatment with the disclosed combination therapy. This analysis involves analyzing expression levels of a predetermined set genes where specific changes in the expression levels of these genes correlates with the biological activities affected by the disclosed combination therapy.
More specifically, identification of elevated levels of expression of selected genes is used to identify patients that are proper candidates for treatment with the GHR antagonist plus cancer therapeutic agent.
More specifically, identification of elevated levels of expression of selected genes is used to identify patients that are proper candidates for treatment with the GHR antagonist plus cancer therapeutic agent.
[0053] Genes whose expression levels are key indicators of effective responsiveness to the disclosed GHR antagonist plus cancer therapy treatment include GHR, PRLR or both GHR and PRLR. Expression levels in a tumor biopsy are measured and quantified by performing a diagnostic test that measures levels of mRNA encoding these proteins that is expressed by the tumor cells. For example, the tumor biopsy sample could be processed to isolate mRNA which is then reverse transcribed into cDNA. The amount of cDNA derived from genes that encode these two receptors could then be measured using a variety of standard assays including qPCR analysis or gene chip analysis. Patients whose tumors express elevated levels of GHR, PRLR or both GHR
and PRLR are potential candidates for receiving treatment with the disclosed combination therapy.
Alternatively, the levels of these target proteins could be measured using techniques that directly measure the amount of these proteins present in the tumor. This approach includes the use of assays such as Western blots or ELISA assays.
and PRLR are potential candidates for receiving treatment with the disclosed combination therapy.
Alternatively, the levels of these target proteins could be measured using techniques that directly measure the amount of these proteins present in the tumor. This approach includes the use of assays such as Western blots or ELISA assays.
[0054] Additional genes whose expression levels are key indicators of effective response to the disclosed hGHR antagonist plus cancer therapeutic combination therapy include a key set of ATP-binding cassette (ABC) drug efflux pumps; ABCB1, ABCB5, ABCB8, ABCC1, ABCC2, ABCG1 and ABCG2. As with the target receptors described above, elevated levels of expression of at least some of these proteins identifies patients for which the disclosed combination hGHR
antagonist plus cancer therapeutic agent would be effective. The levels of expression of these key genes are determined using the analytical techniques described above on samples derived from patient biopsies.
antagonist plus cancer therapeutic agent would be effective. The levels of expression of these key genes are determined using the analytical techniques described above on samples derived from patient biopsies.
[0055] In addition to the drug efflux pump proteins discussed herein, expression levels of a selected set of genes involved in promoting the adverse progression of cancer driven by the Epithelial to Mesenchymal Transition (EMT) can be measured. The set of key EMT
modulators analyzed in a preliminary diagnostic analysis of a patient biopsy include CDH1, CDH2, SNAIL
SNAI2, TGFB1, TGFB2, TGFB3, TGFBR2, TWIST1, TWIST2, VIM, ZEB1 and ZEB2.
Elevated levels of expression of these genes further identify patients that are candidates for effective treatment with the disclosed combination GHR antagonist plus cancer therapeutic agent. The levels of expression of these genes would be determined by the analytical methods described above.
modulators analyzed in a preliminary diagnostic analysis of a patient biopsy include CDH1, CDH2, SNAIL
SNAI2, TGFB1, TGFB2, TGFB3, TGFBR2, TWIST1, TWIST2, VIM, ZEB1 and ZEB2.
Elevated levels of expression of these genes further identify patients that are candidates for effective treatment with the disclosed combination GHR antagonist plus cancer therapeutic agent. The levels of expression of these genes would be determined by the analytical methods described above.
[0056] In addition to the target receptors GHR and PRLR, Insulin Like Growth Factor 1 (IGF-1), Insulin Like Growth Factor Binding Protein 3 (IGFBP3), suppressor of cytokine signaling (SOCS) -1, -2, -3, and cytokine inducible SH2 containing protein (CISH) are important genes whose (RNA or protein) expression levels in the tumor biopsy (all the above) or serum (IGF1 and IGFBP3) can be used to identify patients who will respond effectively to treatment with the disclosed GHR antagonist. As with the target receptor proteins, the levels of these GH inducible downstream signaling factors are determined by gene expression analysis using mRNA gene expression techniques or, preferably, serum protein quantification techniques.
IGF-1, IGFBP3, SOCS-1, -2, -3 and CISH are particularly useful for identifying patients that would be effectively treated by continuing administration of the GHR antagonist following completion of a combination therapy using GHR antagonist plus cancer chemotherapeutic agent.
IGF-1, IGFBP3, SOCS-1, -2, -3 and CISH are particularly useful for identifying patients that would be effectively treated by continuing administration of the GHR antagonist following completion of a combination therapy using GHR antagonist plus cancer chemotherapeutic agent.
[0057] All literature and similar material cited in this application, including, but not limited to, patents, patent applications, articles, books, treatises, and web pages, regardless of the format of such literature and similar materials, are expressly incorporated by reference in their entirety.
Should one or more of the incorporated references and similar materials differs from or contradicts this application, including but not limited to defined terms, term usage, described techniques, or the like, this application controls.
Should one or more of the incorporated references and similar materials differs from or contradicts this application, including but not limited to defined terms, term usage, described techniques, or the like, this application controls.
[0058] As previously stated and as used herein, the singular forms "a,"
"an," and "the,"
refer to both the singular as well as plural, unless the context clearly indicates otherwise. The term "comprising" as used herein is synonymous with "including," "containing," or "characterized by,"
and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. Although many methods and materials similar or equivalent to those described herein can be used, particular suitable methods and materials are described herein.
Unless context indicates otherwise, the recitations of numerical ranges by endpoints include all numbers subsumed within that range. Furthermore, references to "one implementation" are not intended to be interpreted as excluding the existence of additional implementations that also incorporate the recited features.
Moreover, unless explicitly stated to the contrary, implementations "comprising" or "having" an element or a plurality of elements having a particular property may include additional elements whether or not they have that property.
"an," and "the,"
refer to both the singular as well as plural, unless the context clearly indicates otherwise. The term "comprising" as used herein is synonymous with "including," "containing," or "characterized by,"
and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. Although many methods and materials similar or equivalent to those described herein can be used, particular suitable methods and materials are described herein.
Unless context indicates otherwise, the recitations of numerical ranges by endpoints include all numbers subsumed within that range. Furthermore, references to "one implementation" are not intended to be interpreted as excluding the existence of additional implementations that also incorporate the recited features.
Moreover, unless explicitly stated to the contrary, implementations "comprising" or "having" an element or a plurality of elements having a particular property may include additional elements whether or not they have that property.
[0059] The terms "substantially" and "about" used throughout this specification are used to describe and account for small fluctuations, such as due to variations in processing. For example, these terms can refer to less than or equal to 5%, such as less than or equal to 2%, such as less than or equal to 1%, such as less than or equal to 0.5%, such as less than or equal to 0.2%, such as less than or equal to 0.1%, such as less than or equal to 0.05%, and/or 0%.
[0060] Underlined and/or italicized headings and subheadings are used for convenience only, do not limit the disclosed subject matter, and are not referred to in connection with the interpretation of the description of the disclosed subject matter. All structural and functional equivalents to the elements of the various implementations described throughout this disclosure that are known or later come to be known to those of ordinary skill in the art are expressly incorporated herein by reference and intended to be encompassed by the disclosed subject matter.
Moreover, nothing disclosed herein is intended to be dedicated to the public regardless of whether such disclosure is explicitly recited in the above description.
Moreover, nothing disclosed herein is intended to be dedicated to the public regardless of whether such disclosure is explicitly recited in the above description.
[0061] There may be many alternate ways to implement the disclosed inventive subject matter. Various functions and elements described herein may be partitioned differently from those shown without departing from the scope of the disclosed inventive subject matter. Generic principles defined herein may be applied to other implementations. Different numbers of a given module or unit may be employed, a different type or types of a given module or unit may be employed, a given module or unit may be added, or a given module or unit may be omitted.
[0062] Regarding this disclosure, the term "a plurality of' refers to two or more than two.
Unless otherwise clearly defined, orientation or positional relations indicated by terms such as "upper" and "lower" are based on the orientation or positional relations as shown in the figures, only for facilitating description of the present invention and simplifying the description, rather than indicating or implying that the referred devices or elements must be in a particular orientation or constructed or operated in the particular orientation, and therefore they should not be construed as limiting the present invention. The terms "connected", "mounted", "fixed", etc. should be understood in a broad sense. For example, "connected" may be a fixed connection, a detachable connection, or an integral connection; a direct connection, or an indirect connection through an intermediate medium. For an ordinary skilled in the art, the specific meaning of the above terms in the present invention may be understood according to specific circumstances.
Unless otherwise clearly defined, orientation or positional relations indicated by terms such as "upper" and "lower" are based on the orientation or positional relations as shown in the figures, only for facilitating description of the present invention and simplifying the description, rather than indicating or implying that the referred devices or elements must be in a particular orientation or constructed or operated in the particular orientation, and therefore they should not be construed as limiting the present invention. The terms "connected", "mounted", "fixed", etc. should be understood in a broad sense. For example, "connected" may be a fixed connection, a detachable connection, or an integral connection; a direct connection, or an indirect connection through an intermediate medium. For an ordinary skilled in the art, the specific meaning of the above terms in the present invention may be understood according to specific circumstances.
[0063] It should be appreciated that all combinations of the foregoing concepts and additional concepts discussed in greater detail herein (provided such concepts are not mutually inconsistent) are contemplated as being part of the disclosed inventive subject matter. In particular, all combinations of claimed subject matter appearing at the end of this disclosure are contemplated as being part of the inventive subject matter disclosed herein. While the disclosed inventive subject matter has been illustrated by the description of example implementations, and while the example implementations have been described in certain detail, there is no intention to restrict or in any way limit the scope of the appended claims to such detail. Additional advantages and modifications will readily appear to those skilled in the art. Therefore, the disclosed inventive subject matter in its broader aspects is not limited to any of the specific details, representative devices and methods, and/or illustrative examples shown and described. Accordingly, departures may be made from such details without departing from the spirit or scope of the general inventive concept.
[0064] The following references form part of the specification of the present application and each reference is incorporated by reference herein, in its entirety, for all purposes.
1. Pasut, G. and Veronese, M. (2012) State of the Art in Pegylation: The Great Versatility Achieved After Forty Years of Research. J. Controlled Release 161, 461 ¨ 472.
2. Parveen, S. and Sahoo, S.K. Nanomedicine: Clinical Applications of Polyethylene Glycol Conjugated to Proteins and Drugs Clin. Pharmacokinet. 45, 965 ¨ 988.
3. Alconcel, S.N.S., Baas, A.S. and Maynard, H.D. (2011) FDA-Approved Poly(ethylene glycol)-Protein Conjugate Drugs. Polymer Chemistry 2, 1442 ¨
1448.
4. Kling, J. (2013) Pegylation of Biologics: A Multipurpose Solution.
Bioprocess International 11, 35 ¨ 43.
5. Perry, J.K., Wu, Z.-S., Mertani, H.C., Zhu, T., and Lobie, P.E. (2017) "Tumour-Derived Human Growth Hormone as a Therapeutic Target in Oncology" Trends in Endocrinology and Metabolism 28: 587 ¨ 596.
6. Basu, R., Qian, Y., and Kopchick, J.J. (2018) "Lessons from growth hormone receptor gene-disrupted mice: are there benefits of endocrine defects?"
European Journal of Endocrinology 178: R155 ¨ R181.
7. Goffin, V. (2017) "Prolactin Receptor Targeting in Breast and Prostate Cancers:
New Insights into an Old Challenge" Pharmacology and Therapeutics 179: 111-126.
8. Sustarsic, E.G., Junnila, R.K., and Kopchick, J.J. (2013) "Human Metastatic Melanoma Cell Lines Express High Levels of Growth Hormone Receptor and Respond to GH Treatment" Biochem Biophys Res Commun. 441: 144 ¨ 150.
9. Bukowski, K., Kciuk, M., and Kontek, R. (2020) "Mechanisms of Multidrug Resistance in Cancer Chemotherapy" Int. J. Mol. Sci. 21, 3233 10. Basu, R., and Kopchick, J.J. (2019) "The Effects of Growth Hormone on Therapy Resistance in Cancer" Cancer Drug Resistance 2: 827 ¨ 846.
11. Wu, A.M.L., Dalvi, P., Lu, X., Yang, M., Riddick, D.S., et al. (2013) "Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells"
Molecular Pharmacology 83: 377 ¨ 388.
12. Neradugomma, N.K., Subramaniam, D., Tawfik, 0.W., Goffin, V., Kumar, T.R., et al. (2014) "Prolactin signaling enhances colon cancer stemness by modulating Notch signaling in a Jak2-STAT3/ERK manner" Carcinogenesis 35: 795 ¨ 806.
13. Zatelli, M.C., Minoia, M., Mole, D., Cason, V., Tagliati, F., Margutti, A., Bondanelli, M., Ambrosio, M.R., and Uberti, E.d (2009) "Growth Hormone Excess Promotes Breast Cancer Chemoresistance" Journal of Clinical Endocrinology and Metabolism 94: 3931 ¨3938.
14. Minoia, M., Gentilin, E., Mole, D., Rossi, M., Filieri, C., Tagliati, F., Baroni, A., Ambrosio, M.R., and Uberti, E.d, Zatelli, M.C. "Growth Hormone Receptor Blockade Inhibits Growth Hormone-Induced Chemoresistance by Restoring Cytotoxic-Induced Apoptosis in Breast Cancer Cells Independently of Estrogen Receptor Expression" Journal of Clinical Endocrinology and Metabolism 97: E907 ¨ E916.
SEQUENCE LISTING
<210> 1 <211> 576 <212> DNA
<213> Artificial Sequence <220>
<223> hGH antagonist G120K
<400> 1 ttcccaacca ttcccttatc caggcttttt gacaacgcta tgctccgcgc ccatcgtctg 60 caccagctgg cctttgacac ctaccaggag tttgaagaag cctatatccc aaaggaacag 120 aagtattcat tcctgcagaa cccccagacc tccctctgtt tctcagagtc tattccgaca 180 ccctccaaca gggaggaaac acaacagaaa tccaacctag agctgctccg catctccctg 240 ctgctcatcc agtcgtggct ggagcccgtg cagttcctca ggagtgtctt cgccaacagc 300 ctggtgtacg gcgcctctga cagcaacgtc tatgacctcc taaaggacct agaggaaaag 360 atccaaacgc tgatggggag gctggaagat ggcagccccc ggactgggca gatcttcaag 420 cagacctaca gcaagttcga cacaaactca cacaacgatg acgcactact caagaactac 480 gggctgctct actgcttcag gaaggacatg gacaaggtcg agacattcct gcgcatcgtg 540 cagtgccgct ctgtggaggg cagctgtggc ttctag 576 <210> 2 <211> 191 <212> PRT
<213> Artificial Sequence <220>
<223> hGH antagonist G120K
<400> 2 Phe Pro Thr Ile Pro Leu Ser Arg Leu Phe Asp Asn Ala Met Leu Arg Ala His Arg Leu His Gln Leu Ala Phe Asp Thr Tyr Gln Glu Phe Glu Glu Ala Tyr Ile Pro Lys Glu Gln Lys Tyr Ser Phe Leu Gln Asn Pro Gln Thr Ser Leu Cys Phe Ser Glu Ser Ile Pro Thr Pro Ser Asn Arg Glu Glu Thr Gln Gln Lys Ser Asn Leu Glu Leu Leu Arg Ile Ser Leu
1. Pasut, G. and Veronese, M. (2012) State of the Art in Pegylation: The Great Versatility Achieved After Forty Years of Research. J. Controlled Release 161, 461 ¨ 472.
2. Parveen, S. and Sahoo, S.K. Nanomedicine: Clinical Applications of Polyethylene Glycol Conjugated to Proteins and Drugs Clin. Pharmacokinet. 45, 965 ¨ 988.
3. Alconcel, S.N.S., Baas, A.S. and Maynard, H.D. (2011) FDA-Approved Poly(ethylene glycol)-Protein Conjugate Drugs. Polymer Chemistry 2, 1442 ¨
1448.
4. Kling, J. (2013) Pegylation of Biologics: A Multipurpose Solution.
Bioprocess International 11, 35 ¨ 43.
5. Perry, J.K., Wu, Z.-S., Mertani, H.C., Zhu, T., and Lobie, P.E. (2017) "Tumour-Derived Human Growth Hormone as a Therapeutic Target in Oncology" Trends in Endocrinology and Metabolism 28: 587 ¨ 596.
6. Basu, R., Qian, Y., and Kopchick, J.J. (2018) "Lessons from growth hormone receptor gene-disrupted mice: are there benefits of endocrine defects?"
European Journal of Endocrinology 178: R155 ¨ R181.
7. Goffin, V. (2017) "Prolactin Receptor Targeting in Breast and Prostate Cancers:
New Insights into an Old Challenge" Pharmacology and Therapeutics 179: 111-126.
8. Sustarsic, E.G., Junnila, R.K., and Kopchick, J.J. (2013) "Human Metastatic Melanoma Cell Lines Express High Levels of Growth Hormone Receptor and Respond to GH Treatment" Biochem Biophys Res Commun. 441: 144 ¨ 150.
9. Bukowski, K., Kciuk, M., and Kontek, R. (2020) "Mechanisms of Multidrug Resistance in Cancer Chemotherapy" Int. J. Mol. Sci. 21, 3233 10. Basu, R., and Kopchick, J.J. (2019) "The Effects of Growth Hormone on Therapy Resistance in Cancer" Cancer Drug Resistance 2: 827 ¨ 846.
11. Wu, A.M.L., Dalvi, P., Lu, X., Yang, M., Riddick, D.S., et al. (2013) "Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells"
Molecular Pharmacology 83: 377 ¨ 388.
12. Neradugomma, N.K., Subramaniam, D., Tawfik, 0.W., Goffin, V., Kumar, T.R., et al. (2014) "Prolactin signaling enhances colon cancer stemness by modulating Notch signaling in a Jak2-STAT3/ERK manner" Carcinogenesis 35: 795 ¨ 806.
13. Zatelli, M.C., Minoia, M., Mole, D., Cason, V., Tagliati, F., Margutti, A., Bondanelli, M., Ambrosio, M.R., and Uberti, E.d (2009) "Growth Hormone Excess Promotes Breast Cancer Chemoresistance" Journal of Clinical Endocrinology and Metabolism 94: 3931 ¨3938.
14. Minoia, M., Gentilin, E., Mole, D., Rossi, M., Filieri, C., Tagliati, F., Baroni, A., Ambrosio, M.R., and Uberti, E.d, Zatelli, M.C. "Growth Hormone Receptor Blockade Inhibits Growth Hormone-Induced Chemoresistance by Restoring Cytotoxic-Induced Apoptosis in Breast Cancer Cells Independently of Estrogen Receptor Expression" Journal of Clinical Endocrinology and Metabolism 97: E907 ¨ E916.
SEQUENCE LISTING
<210> 1 <211> 576 <212> DNA
<213> Artificial Sequence <220>
<223> hGH antagonist G120K
<400> 1 ttcccaacca ttcccttatc caggcttttt gacaacgcta tgctccgcgc ccatcgtctg 60 caccagctgg cctttgacac ctaccaggag tttgaagaag cctatatccc aaaggaacag 120 aagtattcat tcctgcagaa cccccagacc tccctctgtt tctcagagtc tattccgaca 180 ccctccaaca gggaggaaac acaacagaaa tccaacctag agctgctccg catctccctg 240 ctgctcatcc agtcgtggct ggagcccgtg cagttcctca ggagtgtctt cgccaacagc 300 ctggtgtacg gcgcctctga cagcaacgtc tatgacctcc taaaggacct agaggaaaag 360 atccaaacgc tgatggggag gctggaagat ggcagccccc ggactgggca gatcttcaag 420 cagacctaca gcaagttcga cacaaactca cacaacgatg acgcactact caagaactac 480 gggctgctct actgcttcag gaaggacatg gacaaggtcg agacattcct gcgcatcgtg 540 cagtgccgct ctgtggaggg cagctgtggc ttctag 576 <210> 2 <211> 191 <212> PRT
<213> Artificial Sequence <220>
<223> hGH antagonist G120K
<400> 2 Phe Pro Thr Ile Pro Leu Ser Arg Leu Phe Asp Asn Ala Met Leu Arg Ala His Arg Leu His Gln Leu Ala Phe Asp Thr Tyr Gln Glu Phe Glu Glu Ala Tyr Ile Pro Lys Glu Gln Lys Tyr Ser Phe Leu Gln Asn Pro Gln Thr Ser Leu Cys Phe Ser Glu Ser Ile Pro Thr Pro Ser Asn Arg Glu Glu Thr Gln Gln Lys Ser Asn Leu Glu Leu Leu Arg Ile Ser Leu
65 70 75 80 Leu Leu Ile Gln Ser Trp Leu Glu Pro Val Gln Phe Leu Arg Ser Val Phe Ala Asn Ser Leu Val Tyr Gly Ala Ser Asp Ser Asn Val Tyr Asp Leu Leu Lys Asp Leu Glu Glu Lys Ile Gln Thr Leu Met Gly Arg Leu Glu Asp Gly Ser Pro Arg Thr Gly Gln Ile Phe Lys Gln Thr Tyr Ser Lys Phe Asp Thr Asn Ser His Asn Asp Asp Ala Leu Leu Lys Asn Tyr Gly Leu Leu Tyr Cys Phe Arg Lys Asp Met Asp Lys Val Glu Thr Phe Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe <210> 3 <211> 576 <212> DNA
<213> Artificial Sequence <220>
<223> G120K-H151C-T142C-dPEGA2 (DNA) Synthetic Constructs/Mutant Human Growth Hormone Antagonists <400> 3 ttcccaacca ttcccttatc caggcttttt gacaacgcta tgctccgcgc ccatcgtctg 60 caccagctgg cctttgacac ctaccaggag tttgaagaag cctatatccc aaaggaacag 120 aagtattcat tcctgcagaa cccccagacc tccctctgtt tctcagagtc tattccgaca 180 ccctccaaca gggaggaaac acaacagaaa tccaacctag agctgctccg catctccctg 240 ctgctcatcc agtcgtggct ggagcccgtg cagttcctca ggagtgtctt cgccaacagc 300 ctggtgtacg gcgcctctga cagcaacgtc tatgacctcc taaaggacct agaggaaaag 360 atccaaacgc tgatggggag gctggaagat ggcagccccc ggactgggca gatcttcaag 420 cagtgctaca gcaagttcga cacaaactca tgcaacgatg acgcactact caagaactac 480 gggctgctct actgcttcag gaaggacatg gacaaggtcg agacattcct gcgcatcgtg 540 cagtgccgct ctgtggaggg cagctgtggc ttctag 576 <210> 4 <211> 191 <212> PRT
<213> Artificial Sequence <220>
<223> G120K-H151C-T142C-dPEGA2 (amino acid) Synthetic Constructs /
Mutant Human Growth Hormone Antagonists <400> 4 Phe Pro Thr Ile Pro Leu Ser Arg Leu Phe Asp Asn Ala Met Leu Arg Ala His Arg Leu His Gin Leu Ala Phe Asp Thr Tyr Gin Glu Phe Glu Glu Ala Tyr Ile Pro Lys Glu Gin Lys Tyr Ser Phe Leu Gin Asn Pro Gin Thr Ser Leu Cys Phe Ser Glu Ser Ile Pro Thr Pro Ser Asn Arg Glu Glu Thr Gin Gin Lys Ser Asn Leu Glu Leu Leu Arg Ile Ser Leu Leu Leu Ile Gin Ser Trp Leu Glu Pro Val Gin Phe Leu Arg Ser Val Phe Ala Asn Ser Leu Val Tyr Gly Ala Ser Asp Ser Asn Val Tyr Asp Leu Leu Lys Asp Leu Glu Glu Lys Ile Gln Thr Leu Met Gly Arg Leu Glu Asp Gly Ser Pro Arg Thr Gly Gln Ile Phe Lys Gln Cys Tyr Ser Lys Phe Asp Thr Asn Ser Cys Asn Asp Asp Ala Leu Leu Lys Asn Tyr Gly Leu Leu Tyr Cys Phe Arg Lys Asp Met Asp Lys Val Glu Thr Phe Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
<213> Artificial Sequence <220>
<223> G120K-H151C-T142C-dPEGA2 (DNA) Synthetic Constructs/Mutant Human Growth Hormone Antagonists <400> 3 ttcccaacca ttcccttatc caggcttttt gacaacgcta tgctccgcgc ccatcgtctg 60 caccagctgg cctttgacac ctaccaggag tttgaagaag cctatatccc aaaggaacag 120 aagtattcat tcctgcagaa cccccagacc tccctctgtt tctcagagtc tattccgaca 180 ccctccaaca gggaggaaac acaacagaaa tccaacctag agctgctccg catctccctg 240 ctgctcatcc agtcgtggct ggagcccgtg cagttcctca ggagtgtctt cgccaacagc 300 ctggtgtacg gcgcctctga cagcaacgtc tatgacctcc taaaggacct agaggaaaag 360 atccaaacgc tgatggggag gctggaagat ggcagccccc ggactgggca gatcttcaag 420 cagtgctaca gcaagttcga cacaaactca tgcaacgatg acgcactact caagaactac 480 gggctgctct actgcttcag gaaggacatg gacaaggtcg agacattcct gcgcatcgtg 540 cagtgccgct ctgtggaggg cagctgtggc ttctag 576 <210> 4 <211> 191 <212> PRT
<213> Artificial Sequence <220>
<223> G120K-H151C-T142C-dPEGA2 (amino acid) Synthetic Constructs /
Mutant Human Growth Hormone Antagonists <400> 4 Phe Pro Thr Ile Pro Leu Ser Arg Leu Phe Asp Asn Ala Met Leu Arg Ala His Arg Leu His Gin Leu Ala Phe Asp Thr Tyr Gin Glu Phe Glu Glu Ala Tyr Ile Pro Lys Glu Gin Lys Tyr Ser Phe Leu Gin Asn Pro Gin Thr Ser Leu Cys Phe Ser Glu Ser Ile Pro Thr Pro Ser Asn Arg Glu Glu Thr Gin Gin Lys Ser Asn Leu Glu Leu Leu Arg Ile Ser Leu Leu Leu Ile Gin Ser Trp Leu Glu Pro Val Gin Phe Leu Arg Ser Val Phe Ala Asn Ser Leu Val Tyr Gly Ala Ser Asp Ser Asn Val Tyr Asp Leu Leu Lys Asp Leu Glu Glu Lys Ile Gln Thr Leu Met Gly Arg Leu Glu Asp Gly Ser Pro Arg Thr Gly Gln Ile Phe Lys Gln Cys Tyr Ser Lys Phe Asp Thr Asn Ser Cys Asn Asp Asp Ala Leu Leu Lys Asn Tyr Gly Leu Leu Tyr Cys Phe Arg Lys Asp Met Asp Lys Val Glu Thr Phe Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
Claims (49)
1. A composition for treating a disease or condition responsive to human growth hormone receptor antagonists, comprising:
(a) a modified human growth hormone receptor antagonist; and (b) an anti-cancer composition.
(a) a modified human growth hormone receptor antagonist; and (b) an anti-cancer composition.
2. The composition of claim 1, wherein the disease or condition responsive to human growth hormone receptor antagonists is a cancer that expresses predetermined levels of growth hormone receptor (GHR); predetermined levels of prolactin receptor (PRLR);
predetermined levels of both GHR and PRLR); predetermined levels of ATP-binding cassette (ABC)-transporters; or predetermined levels of epithelial to mesenchymal transition (EMT) mediators.
predetermined levels of both GHR and PRLR); predetermined levels of ATP-binding cassette (ABC)-transporters; or predetermined levels of epithelial to mesenchymal transition (EMT) mediators.
3. The composition of claim 1, wherein the disease or condition responsive to human growth hormone receptor antagonists is cancer, and wherein the cancer is breast cancer, central nervous system cancer, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, renal cancer, pancreatic cancer, endometrial cancer, meningioma, colorectal cancer, colon cancer, neuroblastoma, stomach cancer, liver cancer, lymphoma, combinations thereof, or any other cancer expressing predetermined amounts of GEIR, PRLR, ABC transporters, EMT mediators, or combinations thereof
4. The composition of claim 1, wherein the modified human growth hormone receptor antagonist comprises :
(a) human growth hormone receptor antagonist G120K wherein two amino acids of human growth hormone receptor antagonist G120K have been changed to cysteine, wherein the two amino acids changed to cysteine are T142 and H151; and (b) a polyethylene glycol molecule conjugated to each substituted cysteine in the human growth hormone receptor antagonist G120K-H151C-T142C, wherein the polyethylene glycol molecules conjugated to the two amino acids changed to cysteine are two 4.5 kDa branched polyethylene glycols each containing three carboxylate anions.
(a) human growth hormone receptor antagonist G120K wherein two amino acids of human growth hormone receptor antagonist G120K have been changed to cysteine, wherein the two amino acids changed to cysteine are T142 and H151; and (b) a polyethylene glycol molecule conjugated to each substituted cysteine in the human growth hormone receptor antagonist G120K-H151C-T142C, wherein the polyethylene glycol molecules conjugated to the two amino acids changed to cysteine are two 4.5 kDa branched polyethylene glycols each containing three carboxylate anions.
5. The composition of claim 4, wherein the human growth hormone receptor antagonist G120K has a DNA sequence of SEQ ID NO: 1, and an amino acid sequence of SEQ ID
NO: 2.
NO: 2.
6. The composition of claim 4, wherein the human growth hormone receptor antagonist G120K-H151C-T142C has a DNA sequence of SEQ ID NO: 3, and an amino acid sequence of SEQ ID NO: 4.
7. The composition of claim 4, wherein the following amino acid substitutions have been made: H18D, H21N, R167N, K168A, D1715, K172R, E1745, and I179T, and wherein these mutations are operative to prevent binding to a prolactin receptor.
8. The composition of claim 7, wherein the composition is adapted for the treatment of acromegaly.
9 The composition of claim 4, wherein the polyethylene glycol molecule is prepared by stepwise organic chemistry and is a substantially pure single compound, and wherein the polyethylene glycol molecule is a branched structure.
10. The composition of claim 4, wherein the polyethylene glycol molecule contains a maleimide group for conjugation to a free sulfhydryl group.
11. The composition of claim 1, wherein the anti-cancer composition is an alkylating agent; an antimetabolite; a plant alkaloid; an antitumor antibiotic; or combinations thereof.
12. The composition of claim 11, wherein the alkylating agent is chlorambucil, cyclophosphamide, thiotepa, busulfan, cisplatin, or combinations thereof.
13. The composition of claim 11, wherein the antimetabolite is gemcitabine, 5-fluorouracil, 6-mercaptopurine, cytarabine, or combinations thereof.
14. The composition of claim 11, wherein the plant alkaloid is vincristine, paclitaxel, etoposide, irinotecan, or combinations thereof.
15. The composition of claim 11, wherein the antitumor antibiotic is doxorubicin, dactinomycin, mitoxantrone, idarubicin, or combinations thereof.
16. The composition of claim 1, wherein the anti-cancer composition is a targeted therapy.
17. The composition of claim 16, wherein the targeted therapy includes vemurafenib.
18. A method for treating diseases or conditions responsive to human growth hormone receptor antagonists, comprising administering to a patient an effective amount of the composition of claim 1.
19. A composition for treating a disease or condition responsive to human growth hormone receptor antagonists, comprising:
(a) a modified human growth hormone receptor antagonist, wherein the human growth hormone receptor antagonist comprises:
(i) human growth hormone receptor antagonist G120K wherein two amino acids of human growth hormone receptor antagonist G120K have been changed to cysteine, wherein the two amino acids changed to cysteine are T142 and H151; and (ii) a polyethylene glycol molecule conjugated to each substituted cysteine in the human growth hormone receptor antagonist G120K-H151C-T142C, wherein the polyethylene glycol molecules conjugated to the two amino acids changed to cysteine are two 4.5 kDa branched polyethylene glycols each containing three carboxylate anions, wherein the polyethylene glycol molecule is prepared by step-wise organic chemistry and is a substantially pure single compound, and wherein the polyethylene glycol molecule is a branched structure; and (b) an anti-cancer composition.
(a) a modified human growth hormone receptor antagonist, wherein the human growth hormone receptor antagonist comprises:
(i) human growth hormone receptor antagonist G120K wherein two amino acids of human growth hormone receptor antagonist G120K have been changed to cysteine, wherein the two amino acids changed to cysteine are T142 and H151; and (ii) a polyethylene glycol molecule conjugated to each substituted cysteine in the human growth hormone receptor antagonist G120K-H151C-T142C, wherein the polyethylene glycol molecules conjugated to the two amino acids changed to cysteine are two 4.5 kDa branched polyethylene glycols each containing three carboxylate anions, wherein the polyethylene glycol molecule is prepared by step-wise organic chemistry and is a substantially pure single compound, and wherein the polyethylene glycol molecule is a branched structure; and (b) an anti-cancer composition.
20. The composition of claim 19, wherein the disease or condition responsive to human growth hormone receptor antagonists is a cancer that expresses predetermined levels of growth hormone receptor (GHR); predetermined levels of prolactin receptor (PRLR);
predetermined levels of both GHR and PRLR); predetermined levels of ATP-binding cassette (ABC)-transporters; or predetermined levels of epithelial to mesenchymal transition (EMT) mediators.
predetermined levels of both GHR and PRLR); predetermined levels of ATP-binding cassette (ABC)-transporters; or predetermined levels of epithelial to mesenchymal transition (EMT) mediators.
21. The composition of claim 19, wherein the disease or condition responsive to human growth hormone receptor antagonists is cancer, and wherein the cancer is breast cancer, central nervous system cancer, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, renal cancer, pancreatic cancer, endometrial cancer, meningioma, colorectal cancer, colon cancer, neuroblastoma, stomach cancer, liver cancer, lymphoma, combinations thereof, or any other cancer expressing predetermined amounts of GHR, PRLR, ABC transporters, EMT mediators, or combinations thereof
22. The composition of claim 19, wherein the human growth hormone receptor antagonist G120K has a DNA sequence of SEQ ID NO: 1, and an amino acid sequence of SEQ ID
NO: 2.
NO: 2.
23. The composition of claim 19, wherein the human growth hormone receptor antagonist G120K-H151C-T142-C has a DNA sequence of SEQ ID NO: 3, and an amino acid sequence of SEQ ID NO: 4.
24. The composition of claim 19, wherein the following amino acid substitutions have been made: H18D, H21N, R167N, K168A, D1715, K172R, E1745, and I179T, and wherein these mutations are operative to prevent binding to a prolactin receptor.
25. The composition of claim 24, wherein the composition is adapted for the treatment of acromegaly.
26. The composition of claim 19, wherein the polyethylene glycol molecule contains a maleimide group for conjugation to a free sulfhydryl group.
27. The composition of claim 19, wherein the anti-cancer composition is an alkylating agent;
an antimetabolite; a plant alkaloid; an antitumor antibiotic; or combinations thereof.
an antimetabolite; a plant alkaloid; an antitumor antibiotic; or combinations thereof.
28. The composition of claim 27, wherein the alkylating agent is chlorambucil, cyclophosphamide, thiotepa, busulfan, cisplatin, or combinations thereof.
29. The composition of claim 27, wherein the antimetabolite is gemcitabine, 5-fluorouracil, 6-mercaptopurine, cytarabine, or combinations thereof.
30. The composition of claim 27, wherein the plant alkaloid is vincristine, paclitaxel, etoposide, irinotecan, or combinations thereof.
31. The composition of claim 27, wherein the antitumor antibiotic is doxorubicin, dactinomycin, mitoxantrone, idarubicin, or combinations thereof.
32. The composition of claim 19, wherein the anti-cancer composition is a targeted therapy.
33. The composition of claim 32, wherein the targeted therapy includes vemurafenib.
34. A method for treating diseases or conditions responsive to human growth hormone receptor antagonists, comprising administering to a patient an effective amount of the composition of claim 19.
35. A method for treating cancer using human growth hormone antagonists, comprising:
(a) pre-screening a patient by analyzing a tumor biopsy to confirm the presence of cancer and the presence of certain predetermined factors indicative of responsiveness to human growth hormone antagonists; and (b) treating the patient with an effective amount of a composition that includes a modified human growth hormone receptor antagonist and an anti-cancer composition.
(a) pre-screening a patient by analyzing a tumor biopsy to confirm the presence of cancer and the presence of certain predetermined factors indicative of responsiveness to human growth hormone antagonists; and (b) treating the patient with an effective amount of a composition that includes a modified human growth hormone receptor antagonist and an anti-cancer composition.
36. The method of claim 35, wherein the certain predetermined factors include predetermined levels of GHR, PRLR, ABC transporters, EMT mediators, insulin-like growth factor-1 (IGF-1); IFG binding protein-3 (IGFBP3), suppressor of cytokine signaling (SOCS -1, -2, -3; and cytokine inducible SH2 containing protein (CISH).
37. The method of claim 35, wherein the cancer is breast cancer, central nervous system cancer, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, renal cancer, pancreatic cancer, endometrial cancer, meningioma, colorectal cancer, colon cancer, neuroblastoma, stomach cancer, liver cancer, lymphoma, combinations thereof, or any other cancer expressing predetermined amounts of the predetermined factors.
38. The method of claim 35, wherein the modified human growth hormone receptor antagonist comprises:
(a) human growth hormone receptor antagonist G120K wherein two amino acids of human growth hormone receptor antagonist G120K have been changed to cysteine, wherein the two amino acids changed to cysteine are T142 and H151; and (b) a polyethylene glycol molecule conjugated to each substituted cysteine in the human growth hormone receptor antagonist G120K-H151C-T142C, wherein the polyethylene glycol molecules conjugated to the two amino acids changed to cysteine are two 4.5 kDa branched polyethylene glycols each containing three carboxylate anions.
(a) human growth hormone receptor antagonist G120K wherein two amino acids of human growth hormone receptor antagonist G120K have been changed to cysteine, wherein the two amino acids changed to cysteine are T142 and H151; and (b) a polyethylene glycol molecule conjugated to each substituted cysteine in the human growth hormone receptor antagonist G120K-H151C-T142C, wherein the polyethylene glycol molecules conjugated to the two amino acids changed to cysteine are two 4.5 kDa branched polyethylene glycols each containing three carboxylate anions.
39. The method of claim 38, wherein the human growth hormone receptor antagonist G120K
has a DNA sequence of SEQ ID NO: 1, and an amino acid sequence of SEQ ID NO:
2.
has a DNA sequence of SEQ ID NO: 1, and an amino acid sequence of SEQ ID NO:
2.
40. The method of claim 38, wherein the human growth hormone receptor antagonist G120K-H151C -T142C has a DNA sequence of SEQ ID NO: 3, and an amino acid sequence of SEQ ID NO: 4.
41. The method of claim 38, wherein the polyethylene glycol molecule is prepared by step-wise organic chemistry and is a substantially pure single compound, and wherein the polyethylene glycol molecule is a branched structure.
42. The method of claim 38, wherein the polyethylene glycol molecule contains a maleimide group for conjugation to a free sulfhydryl group.
43. The method of claim 35, wherein the anti-cancer composition is an alkylating agent; an antimetabolite; a plant alkaloid; an antitumor antibiotic; or combinations thereof.
44. The method of claim 43, wherein the alkylating agent is chlorambucil, cyclophosphamide, thiotepa, busulfan, cisplatin, or combinations thereof
45. The method of claim 43, wherein the antimetabolite is gemcitabine, 5-fluorouracil, 6-mercaptopurine, cytarabine, or combinations thereof.
46. The method of claim 43, wherein the plant alkaloid is vincristine, paclitaxel, etoposide, irinotecan, or combinations thereof
47. The method of claim 43, wherein the antitumor antibiotic is doxorubicin, dactinomycin, mitoxantrone, idarubicin, or combinations thereof.
48. The composition of claim 35, wherein the anti-cancer composition is a targeted therapy.
49. The composition of claim 48, wherein the targeted therapy includes vemurafenib.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/411,497 US11857602B2 (en) | 2019-06-17 | 2021-08-25 | Growth hormone antagonist and anti-cancer composition combination therapy |
US17/411,497 | 2021-08-25 | ||
PCT/US2022/074968 WO2023028430A2 (en) | 2021-08-25 | 2022-08-15 | Growth hormone antagonist and anti-cancer composition combination therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3230155A1 true CA3230155A1 (en) | 2023-03-02 |
Family
ID=85323353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3230155A Pending CA3230155A1 (en) | 2021-08-25 | 2022-08-15 | Growth hormone antagonist and anti-cancer composition combination therapy |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4392055A2 (en) |
JP (1) | JP2024532319A (en) |
CA (1) | CA3230155A1 (en) |
WO (1) | WO2023028430A2 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101415409B (en) * | 2006-04-05 | 2012-12-05 | 诺瓦提斯公司 | Combinations of therapeutic agents for treating cancer |
US20100166747A1 (en) * | 2007-03-02 | 2010-07-01 | Beltran Pedro J | Methods and compositions for treating tumor diseases |
US20170007711A1 (en) * | 2015-07-07 | 2017-01-12 | Richard S. Brody | Pegylated growth hormone antagonists |
US11473088B2 (en) * | 2016-12-02 | 2022-10-18 | Ohio University | Method of treating cancer and method of sensitizing cancer cells to the action of chemotherapeutic agents via growth hormone receptor antagonists or knock down |
JP2022536788A (en) * | 2019-06-17 | 2022-08-18 | モレキュラー テクノロジーズ ラボラトリーズ エルエルシー | PEGylated Growth Hormone Antagonist Therapeutics |
-
2022
- 2022-08-15 JP JP2024512959A patent/JP2024532319A/en active Pending
- 2022-08-15 EP EP22862200.7A patent/EP4392055A2/en active Pending
- 2022-08-15 CA CA3230155A patent/CA3230155A1/en active Pending
- 2022-08-15 WO PCT/US2022/074968 patent/WO2023028430A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP4392055A2 (en) | 2024-07-03 |
JP2024532319A (en) | 2024-09-05 |
WO2023028430A3 (en) | 2023-04-06 |
WO2023028430A2 (en) | 2023-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lu et al. | Targeting growth hormone function: strategies and therapeutic applications | |
Watt et al. | Biology of somatostatin in breast cancer | |
EP3062881B1 (en) | Cancer models and associated methods | |
Khandwala et al. | The effects of insulin-like growth factors on tumorigenesis and neoplastic growth | |
CA2654944C (en) | Stabilized insulin-like growth factor polypeptides | |
Schulz et al. | Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies | |
Zhou et al. | STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion | |
Sustarsic et al. | Human metastatic melanoma cell lines express high levels of growth hormone receptor and respond to GH treatment | |
Yin et al. | Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy | |
AU2014296288B2 (en) | Compositions and methods for modulating thermogenesis using PTH-related and EGF-related molecules | |
Maia et al. | Novel therapies for acromegaly | |
Liu et al. | Design, Synthesis, and Biological Evaluation of 68Ga-DOTA–PA1 for Lung Cancer: A Novel PET Tracer for Multiple Somatostatin Receptor Imaging | |
Ovejero et al. | Octreotide is ineffective in treating tumor‐induced osteomalacia: results of a short‐term therapy | |
JP2024016080A (en) | Therapeutic agents of pegylated growth hormone antagonists | |
US11857602B2 (en) | Growth hormone antagonist and anti-cancer composition combination therapy | |
CA3230155A1 (en) | Growth hormone antagonist and anti-cancer composition combination therapy | |
CN114957491B (en) | Polypeptide and polypeptide derivative for targeting binding beta-catenin protein and application of polypeptide and polypeptide derivative | |
EP1284291A1 (en) | Human pgc-1 promoter | |
US20210169984A1 (en) | Sensitizing cancer to death receptor agonists with kinase inhibitors | |
EP3326624A1 (en) | Immunotherapy for casr-expressing cancer (e.g. neuroblastoma) | |
EP3984547A1 (en) | Peptides for the treatment of cancer | |
EP4122467A1 (en) | Thx-b for treating and preventing cancer and metastasis | |
Danalev et al. | Synthesis, Antiproliferative Effect and In Silico LogP Prediction of BIM-23052 Analogs Containing Tyr Instead of Phe. Pharmaceutics 2023, 15, 1123 | |
JP2020521723A (en) | Methods for diagnosing and treating cachexia | |
Herrera-Martínez et al. | Partially based on: Neuroendocrine tumors: diagnostic, predictive and prognostic markers Aura D Herrera-Martínez., Leo J. Hofland1, Wouter W. de Herder1, María A. Gálvez Moreno2, Justo P. Castaño2 and Richard A. Feelders1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20240222 |
|
EEER | Examination request |
Effective date: 20240222 |